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The mechanical contraction of the heart is tightly coupled to rapid and concerted electrical 
excitation of the cardiac muscle. This electrical activity is facilitated by a highly synchronized 
conduction system consisting of channels, pumps, and transporters that facilitate the flow of 
charged ions between cellular compartments, the cytoplasm, and the interstitial fluid between cells. 
The biophysical properties of these membrane proteins have been studied for many years, but their 
role in the generation of potentially lethal cardiac arrhythmias and their interactions with drugs 
remains an important field of research. The cardiac isoform of the voltage-gated Na+-channel, 
Nav1.5, has garnered widespread interest because of its role in the generation of electrical impulses 
in the cardiac myocyte, its association with congenital conduction disorders and acquired cardiac 
arrhythmias, and its unique pharmacological properties.  
The Congenital Long QT Syndrome Type 3 (LQT3) arises from heritable mutations in 
SCN5A - the gene encoding Nav1.5 - that disrupt the inactivation process responsible for imparting 
a refractory period and that often cause a sustained depolarizing late current (INaL). The gain of 
function depolarizing currents arising from LQT3 mutant channels cause a prolongation of the 
ventricular action potential and leave patients susceptible to asynchronous electrical activity, 
ventricular arrhythmias, and sudden cardiac death. The disruption of channel inactivation can arise 
through a wide range of modalities, including changes in inactivation voltage-dependence and 
kinetics, and has been shown to occur with varying degrees of severity. Because of this range of 
phenotypes there is heterogeneity in the risk factors for arrhythmia and sudden cardiac death and 
	
in the utility of Na+-channel blocking antiarrhythmic drugs. Moreover, INaL has been implicated as 
a proarrhythmic and potentiating factor in several acquired cardiac ailments including heart failure, 
ischemia, and hypertrophy. There is therefore a large unmet need for improved understanding of 
INaL and mechanisms of its selective inhibition, and LQT3 mutant channels provide a reliable 
experimental model for this class of cardiac arrhythmias. 
This study will employ a combination of electrophysiological and computational methods 
to unravel mechanisms by which mutant Nav1.5 produces pro-arrhythmic currents and the 
interactions of different disease-causing mutant channels with a set of clinically relevant 
antiarrhythmic drugs. Chapter 1 of this study presents a functional characterization of one LQT3 
mutation, F1473C, that was discovered in a patient with severe QT prolongation, frequent 
ventricular arrhythmias, and a poor response to pharmacological intervention. This mutation gives 
rise to INaL by a mechanism that is functionally distinct from the mechanism discovered previously 
in the canonical LQT3 mutation, ΔKPQ (1505-1507del), and causes a unique response to channel 
inhibitors. In order to better understand the mechanisms of this divergent pharmacology, Chapter 
2 presents the development of a series of computational models which explore the gating 
dysfunctions that cause INaL and how these pathological changes can influence the predicted safety 
and efficacy of pharmacological intervention. These models predict that the majority of mutation-
specific drug effects can be attributed to differential mutant channel gating, but raise the possibility 
that mutations may directly alter the physical chemical interaction between drugs and channels. 
Finally, Chapter 3 presents an attempt to explore this possibility using an innovative chemical 
biology technique - the site-specific incorporation of unnatural amino acids - that allows for the 
measurement of precise chemical interactions hypothesized to vary in a mutation-dependent 
manner. The findings presented in this work promote the need for patient-specific screening of 
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Cardiac disease is the leading cause of death in the United States2, yet despite decades of 
investigation there remain important properties of cardiac function and pharmacology that are 
poorly understood. The dynamic interplay between ionic currents of the cardiac myocyte and 
changes to those currents that arise during heritable or acquired disease remains a critical area of 
exploration. Of particular interest recently is the role of Na+ in the pathogenesis of lethal cardiac 
arrhythmias3-5. This work will focus on the physiology and molecular machinery of the cardiac 
Na+-current 6 and the important properties of INa inhibitors that have a demonstrated antiarrhythmic 
benefit in the clinic. 
 
The INa Current in Cardiac Electrophysiology 
Electrical signaling in the heart is initiated in the pacemaker cells of the sinoatrial node, 
where hyperpolarization-activated channels gradually depolarize the cell membrane7, 8. A 
synchronized wave of electrical stimulation then flows through the atria, converging on the 
atrioventricular node. From there excitation spreads to the specialized conduction network of the 
ventricle, and ultimately through the ventricular tissue. The 2-dimensional projection of these 3-
dimensional electrical signals results in the characteristic waveform of the electrocardiogram, 
where the P-wave corresponds with atrial depolarization, the QRS-complex with ventricular 
depolarization, and the T-wave with ventricular repolarization. The QT-interval is therefore a 
reliable surrogate measure of the duration of the ventricular action potential and the time to 
ventricular repolarization. 
The ventricular action potential undergoes several distinct phases during a single heartbeat. 
In a healthy heart, the membrane resting potential sits near -85mV 8. The influx of cations from an 
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adjacent cell through gap junctions causes an initial depolarization of the membrane towards the 
activation threshold of the voltage-gated Na+-channel (-55mV) 8, 9, allowing the rapid flow of Na+ 
down its electrochemical gradient. This highly selective current activates extremely rapidly, 
driving the membrane potential towards the reversal potential for Na+, around +50mV. The speed 
and magnitude of INa is therefore essential to the rapid upstroke of the action potential and 
propagation of electrical signals in the heart. Mutations9, 10 or drugs11, 12 which diminish this current 
can be proarrhythmic, making preclinical screening of novel therapeutics an important step in 
demonstrating safety.  
The depolarized membrane has widespread influence on other ionic currents, as well as on 
INa itself. In a healthy heart, INa rapidly attenuates with a t1/2 of ~1ms in a process known as 
inactivation, and contributes little to the net ionic current in later phases of the action potential 
(Figure I1a,b). As INa inactivates, other ionic currents begin to contribute to the action potential 
waveform8. A transient outward K+-current 13 creates a brief notch that is followed by a prolonged 
plateau period in which inward flux of Ca2+ ions (ICaL) and outward K+ flux through delayed 
rectifier K+-channels (IKr and IKs) balance. The influx of Ca2+ during this plateau not only serves 
as an electrical signal, but also as a fundamental chemical signal that couples excitation and 
contraction: cytoplasmic Ca2+ binds to the Ca2+-sensing machinery of the ryanodine receptor 
triggering Ca2+-dependent Ca2+ release from the sarcoplasmic reticulum and removing the troponin 
brake on actin-myosin bridging. Voltage- and Ca2+-dependent inactivation of ICaL and continued 
activation of IKr and IKs cause a gradual repolarization of the membrane to its resting potential after 
approximately 400ms, and Ca2+ extrusion by the Na+/Ca2+ exchanger (NCX) and sarcoplasmic 
reuptake allow the muscle to relax.	 
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As observed first by Hodgkin and Huxley in giant squid axon14, 15, the inactivation process 
in INa is functionally distinct from channel activation and deactivation, or opening and closing. It 
therefore may occur when the channel is either open or closed and displays its own voltage-
dependent activity16 that underlies the refractory period during which the firing of a second action 
potential is not possible (Figure I1c). At hyperpolarized potentials, a very small fraction of 
channels is inactivated, leaving the majority of channels available to open upon membrane 
depolarization. However, at potentials higher than -90mV an increasing fraction of channels 
inactivate and are unable to contribute to INa upon a depolarizing stimulus, resulting in a peak Na+-
Figure I1. Physiology and molecular biology of INa. A) Consecutive recordings of single Na+ channels 
recorded under cell attached conditions in HEK293 cells transfected with Nav1.5 cDNA. B) WT Na+ 
currents recorded under whole-cell patch clamp conditions in HEK293 cells and obtained by 
depolarizations from -120mV to -30mV. At high gain (inset), whole cell currents return nearly to 0nA. 
C) Voltage dependence of activation (■) and inactivation (●). D) Topology of Nav1.5 in the plasma 




transient that decreases as the resting membrane potential increases. This sub-activation threshold 
inactivation, known as steady-state inactivation, results in half of the channels inactivating at 
around -70mV. During depolarizing stimuli above the activation threshold (-50mV) (Figure I1c) 
activation occurs faster than inactivation, resulting in the large inward Na+-transient that decays 
rapidly soon after activation. Upon membrane repolarization channels recover from inactivation 
following a bi-exponential time course, suggesting the presence of at least two functionally and 
structurally distinct inactivated states of the channel. 
 
Structure and Function of Voltage-Gated Na+-Channels 
In the heart, the primary cardiac isoform of the voltage-gated Na+-channel responsible for 
carrying INa is Nav1.5, encoded by the gene SCN5A17. The relationship between channel gating and 
the structural features of Nav1.5 has been studied extensively, but many questions regarding this 
link remain unanswered. Without the benefit of an atomic-scale structure for a eukaryotic Na+-
channel, the majority of our understanding of channel structure is derived from biochemical and 
functional work, with recent contributions from a series of crystal structures from a 
homotetrameric prokaryotic Na+-channel18, 19.  
Nav1.5 is composed of a single polypeptide with 4 homologous domains (DI-DIV) that 
resemble the canonical subunit structures observed in homotetrameric K+-channels9 (Figure I1d). 
These 4 domains arrange around a single asymmetrical conduction pathway. Each domain contains 
6 transmembrane helices (S1-S6) and a reentrant loop between S5 and S6 that serves as the 
selectivity filter. The large aqueous inner cavity is lined by S5 and S6, which also converge at the 
intracellular face of the channel to form the activation gate. The C-terminal ends of S6 cross in the 
closed state of the channel, preventing the flow of ions through the channel. 
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The intracellular loops connecting the domains of Nav1.5 are absolutely critical to channel 
function, in particular the DIII/DIV linker and the large C-terminal domain. The DIII/DIV linker 
contains several structures important in channel inactivation. A three residue segment called the 
‘IFM motif’ (isoleucine, phenylalanine, methionine), has been shown to be the primary 
inactivation particle, responsible for imparting the fast phase of inactivation20, 21. Following 
channel opening, this motif binds to a putative receptor on the inner mouth of the channel22, 23, 
preventing further ionic flux and providing a structural basis for the distinction between channel 
deactivation (closing) and inactivation. In fact, disruption of this interface by proteolysis24 or 
mutation can dramatically impair channel inactivation25. Moreover, the DIII/DIV linker binds 
calmodulin in the Ca2+ bound form and modulates inactivation in a Ca2+ dependent manner26-28. 
An important role for the C-terminus in channel inactivation has also emerged. The 
structured proximal C-terminus contains a collection of six helices29 in part held together by a 
hydrophobic interface30. Disruption of this interface results in impaired inactivation, and several 
naturally occurring point mutations have been identified in patients with congenital arrhythmias13, 
31 (Figure I2a). The structural interface and functional interdependency of the DIII/DIV linker and 
C-terminus remain unclear, but both domains are necessary for rapid and complete inactivation32. 
It has been proposed that this relationship is facilitated by calmodulin27, 28, for which there are 
binding sites on each channel structure. There are also interaction sites for cytoplasmic auxiliary 
proteins which link channels to the cytoskeleton and regulate membrane localization33 (Figure 
I1d). 
The voltage-dependence of activation, inactivation, and deactivation are governed by the 
displacement of four voltage-sensing units comprised of S1-S4 in each domain. The S4 helices 
contain positively charged arginine residues that respond to the electric field across the plasma 
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membrane9. At hyperpolarized membrane potentials, the S4 helix sits toward the inner leaflet of 
the membrane in the resting position. Upon depolarization, the helices are driven upward to an 
activated position, resulting in conformational changes that are transmitted to the channel gating 
machinery. Unlike eukaryotic voltage-gated K+ channels, Nav1.5 is not symmetrical and the four 
voltage-sensing units activate with different voltage-dependencies to control different aspects of 
channel gating34. Mutagenesis35, 36, cysteine accessibility37, and fluorometric38 studies have 
identified contributions from the DIII and DIV voltage sensors as important in the voltage-
dependent properties of inactivation. 
 
Pathophysiology of Late Na+ Current 
The plateau phase of the ventricular action potential is a period of relatively high input 
resistance, so small changes in ionic currents can have a substantial impact on membrane potential. 
As discussed above, in healthy hearts this isoelectric period is maintained by a balance of outward 
K+ flux and inward Ca2+ flux. Loss of this K+ current, gain of Ca2+-current, or gain of another 
depolarizing current can lead to prolongation of the plateau phase, delayed repolarization, and 
prolongation of the QT-interval on the ECG8(Figure I2b). These changes may arise from channel 
mutations, post-translational modifications, or pharmacological targeting of specific currents 
(especially the IKr current). In the case where this depolarizing current is due to aberrant INa, this 





Figure I2. INa dysfunction leading to congenital LQTS. A) Topology of 
Nav1.5 in the plasma membrane. Several representative LQT3-associated 
mutations were selected because there is strong evidence that they induce 
INaL by channel bursting (▲) or by late reopening (●), or prolong the action 
potential without INaL (■). B) ECG from a LQT3 patient (unpublished data). 
C) Representative current recordings from WT (gray) and F1473C (black) 
Nav1.5 expressed in HEK293 cells at low and high gain (inset) elicited by 
depolarization to -10mV 1. D) Simulated action potential (top) and INa 
(bottom) in WT (gray) and heterozygous LQT3 (black) conditions.  INa 
peak current was truncated to enhance view of INaL. E) Steady-state channel 





When INa fails to inactivate or inactivates too slowly the result is a sustained late current 
(INaL) Figure I2c). INaL has been identified in many LQT3-associated mutant channels and often 
amounts to less than 1% of the amplitude of peak INa10. Despite its limited size, sustained INaL has 
been shown sufficient to prolong the ventricular action potential in animal models39, stem-cell 
derived cardiomyocytes40, and computational models41, 42 (Figure I2d). Because the ECG is a body 
surface representation of changes in the electrical field around the heart, action potential 
prolongation is well correlated with prolongation of the QT interval and elevated risk of ventricular 
arrhythmia and sudden cardiac death. Unlike patients with K+-channel associated LQT1 and 
LQT2, patients with LQT3 tend to have an increased risk of arrhythmic events during periods of 
rest43 because, as discussed below, in some LQT3 variants INaL increases with slower pacing 
rates41. However, even within the umbrella of LQT3 there is a moderate degree of phenotypic 
heterogeneity43. The mechanisms underlying this heterogeneity have been studied in depth, and 
several modes of INaL generation have been identified with unique rate-dependent properties13, 44. 
 
Mechanisms of INaL 
Channel Bursting 
The first LQT3 mutation that was identified in Nav1.5 was the ΔKPQ (1505-1507del) 
deletion in the intracellular loop connecting DIII and DIV45. ΔKPQ results in a marked and time-
independent INaL that prolongs the action potential in isolated mouse ventricular myocytes46, 47 and 
Purkinje cells46 and in in silico models of human cardiomyocytes41, 42, 48, 49. While in the majority 
of depolarizing pulses these channels activate and inactivate normally, in less than 1% of cases a 
channel will enter a slow “burst” mode of gating characterized by prolonged periods of channel 
opening that often persist for multiple seconds and across multiple sequential sweeps50. Transitions 
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between the background WT-like gating mode and the burst mode are orders of magnitude slower 
than the conformational changes that govern normal channel gating. In heterologous expression 
systems INaL from ΔKPQ channels displays an inverse rate-dependence with a larger INaL at slower 
pacing frequencies51. This results in pause-induced EADs observed in isolated ΔKPQ mouse 
cardiomyocytes39 and in silico models41, 42. Consequently, LQT3 patients with the ΔKPQ mutation 
are at a higher risk of arrhythmia and sudden cardiac death during periods of rest43, 52. 
Our limited knowledge of the structure of the DIII/DIV linker and inactivation machinery 
provides little structural explanation for the inverse rate-dependence of ΔKPQ, but functional and 
computational work has provided some clues about the gating transitions important in the modal 
shifts. At faster pacing frequencies channels tend to spend more time in inactivated states and less 
time in closed states. Computational analysis revealed that slow transitions into the bursting mode 
from channel closed states can account for the inverse rate-dependence of INaL, as well as the 
frequency of occurrence of bursting events at the single-channel level41. 
 
Late Reopenings 
Several mutations have been identified that cause INaL not due to channel bursting (Figure 
I2a). These mutations, such as R1644H, N1325S, and S1904L, are typically associated with a 
deficiency in fast or slow phases of inactivation. The R1644H and N1325S mutations were 
identified soon after the ΔKPQ mutation and demonstrated unique effects on the kinetics and 
voltage-dependence of inactivation, suggesting that the etiology of INaL in these mutations was 
different53. Single channel analysis revealed dispersed channel reopenings that occurred two orders 




The S1904L mutation was discovered in a patient that experienced palpitations during 
periods of exercise - an uncharacteristic clinical presentation for a patient with LQT313. Whole cell 
experiments revealed a time course of fast inactivation that was slower than WT and INaL that 
decayed gradually over time, unlike the time-independent INaL of ΔKPQ. At the single channel 
level, these channels yielded dispersed late reopenings with a longer mean open duration than WT 
channels, consistent with the delayed time to half inactivation of whole cell INa. These findings 
contributed to our understanding of the role of the C-terminal domain as an important determinant 
of inactivation, and transition metal ion FRET showed that the mutation disrupts an important 
hydrophobic interface in this region55. 
Computational models have been used to characterize the gating defects that give rise to 
these pathological channel properties1. Channel reopening arises due to a deficiency in slow 
inactivation that prolongs the mean dwell time of channels in the fast inactivated state. At 
physiologically relevant voltages there exists an equilibrium between open and fast inactivated 
states the greatly favors inactivation, though not completely. The increased dwell time in this state 
therefore results in an increased probability of S1904L channels reopening. It should be noted, 
however, that there is a small amount of reopening that does occur even from WT channels. 
Eventually the slow inactivated states become fully absorbing, giving rise to the time-dependent 
INaL that decays with prolonged depolarizations. One consequence of this deficiency in 
inactivation, unlike the mode shifts that give rise to channel bursting, is that the reopenings are not 
rate dependent. In fact, reopenings contribute more to action potential prolongation at faster pacing 
frequencies where the slow-decaying INaL is still large during the repolarization phase. Similarly, 
late reopenings may have a larger effect in certain tissue types, such as the Purkinje fiber, where a 
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lower plateau potential further slows the already impaired voltage-dependent inactivation and 
provides a stronger driving force for inward Na+ flux42. 
 
Window Current and Non-Equilibrium Gating 
There exist a number of LQT3-associated mutations which do not produce INaL under 
standard whole cell patch clamp protocols. The near-instantaneous voltage steps used in square-
pulse experiments fail to account for voltage-dependent gating transitions that occur at 
intermediate voltages experienced during gradual membrane repolarization. In WT channels the 
voltage-dependence of conductance and steady-state fast inactivation overlap only very slightly, 
producing a very narrow “window” of current around -70mV where a small fraction of channels 
can activate without inactivating56. Mutations which shift the voltage dependence of inactivation 
in the depolarized direction (Figure I2e), or conductance in the hyperpolarized direction, will 
increase the area under these two curves, resulting in a wider range over which channels may 
activate without inactivating. As the action potential repolarizes back through this range a 
“window current” emerges, providing an aberrant depolarizing Na+-flux that slows repolarization. 
It is also possible that a similar emergence of INa may occur at prolonged times without any 
change in steady-state inactivation properties. For example, the I1768V mutation was identified in 
a patient with LQT3, and functional studies in heterologous expression systems revealed no INaL 
or shift in steady-state inactivation57. However, voltage ramp protocols showed a significant 
increase in late current compared to WT channels. Additional experiments revealed a speeding of 
recovery from inactivation over WT that permits channels to recover prematurely and open again 




Na+-Channel Blockers as Antiarrhythmics 
Clinical Utility in Long QT Syndrome Type 3 
Since the discovery of the role of INaL in the pathology of LQT3 and other acquired 
arrhythmia conditions, the pharmacology of INaL has garnered a lot of interest3, 4, 58, 59. However, 
the importance of peak INa in the upstroke velocity of the action potential and in the rapid 
conduction of electrical impulses through the heart makes the selective inhibition of INaL critically 
important. In fact, the widely cited CAST study reported that the use of the Na+-channel inhibitor 
flecainide to prevent fatal arrhythmias following myocardial infarction resulted in an increase in 
deaths12. Moreover, the pharmacological promiscuity among cardiac ion channels raises the risk 
of off-target effects, such as inhibition of the IKr current, that can be counterproductive in efforts 
to normalize the action potential. LQT3 patients are therefore the most likely of all LQT patients 
to receive invasive implantable cardioverter-defibrillators (ICDs) as a precaution6. There is 
therefore a growing demand for unraveling the mechanisms that contribute to preferential 
inhibition of INaL and for the application of these lessons to the continued development of novel 
and selective drugs60. The majority of Nav-inhibiting drugs are local anesthetics (LAs) or LA-like 
drugs that are useful clinically because of their ability to target INaL (Figure I3). Not long after the 
discovery of the ΔKPQ mutation, experiments in heterologous expression systems demonstrated 
that the commonly used Class 1b antiarrhythmic Lidocaine inhibited INaL with greater potency than 
it inhibited peak INa61. Similar observations have been made in heterologous systems with a large 
number of drugs, including Mexiletine54 (Figure I3a), Ranolazine47 (Figure I3b), 
Flecainide39(Figure I3c), and more recently with the experimental inhibitor GS-96762. Each of 
these drugs has also demonstrated utility in normalizing the action potential or preventing EADs 
in animal models of LQT339, 47, 60. More importantly, the preferential inhibition of INaL by these 
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drugs in humans has been shown to shorten the QT interval63, 64 and reduce the frequency of 
arrhythmic events in patients with LQT365. The suggestion has also been made that preferential 
inhibition of the small fraction of INaL present in WT cardiomyocytes may help to offset the 
proarrhythmic effects of drug-induced QT-prolongation66. 
 
Drug-Channel Interactions 
Local anesthetic drugs bind to a series of conserved residues in the central pore of Nav 
channels. In Nav1.5 the residue that contributes the most to channel inhibition is F1760, located 
just below the selectivity filter on S6 of DIV67. Mutation of this residue to alanine ablates UDB by 
Lidocaine68, Mexiletine69, Ranolazine47, Flecainide68, GS-96762 and others. These inhibitors vary 
in their size, charge, and hydrophobicity, and have therefore contributed to our understanding of 
Figure I3. Representative recordings at low and high (insets) gain of F1473C inhibition by A) 50µM 
Mexiletine, B) 50µM Ranolazine, and C) 10µM Flecainide. D) Mexiletine, Ranolazine, and 
Flecainide inhibit INa with preference for INaL. Figure reproduced from Bankston, et al.1 
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the mechanisms important in INaL block. There are two factors important in their function: state-
dependence of drug binding and access to the occluded binding site. 
On the basis of use-dependent block (UDB) - where channel inhibition accumulates with 
repetitive pulsing – and shifts in the voltage-dependence of inactivation, Hille proposed the 
Modulated Receptor Hypothesis70. In simple terms this hypothesis posits that local anesthetics 
bind to a common receptor site with selective affinity to certain channel states and exerts an 
allosteric stabilization of those states. High affinity block of open or inactivated channels allows 
for the accumulation of non-conducting blocked channels during faster pacing frequencies and 
recovery from channel block during periods of rest71. Biochemical37, 72, 73 and fluorometric74 
analysis of channel conformations has provided additional evidence that the binding of local 
anesthetics alters the distribution of channel states to favor slow inactivation. In the presence of 
Lidocaine, the voltage sensors that are responsible for voltage-dependent inactivation accumulate 
in their activated position, linking drug binding with allosteric modulation of channel gating. 
The cationic form of these molecules imparts stronger UDB than the neutral forms75, 
raising the question of how binding of a charged species relies so heavily on the aromatic F1760. 
Using a series of unnatural derivatives of F1760 that monotonically diminish the density of 
aromatic π-electrons, Ahern and Horn demonstrated that a cation-π interaction is responsible for 
imparting UDB, but not tonic block, by Lidocaine76. It is likely, therefore, that conformational 
changes in the pore during activation and inactivation create favorable conditions for the formation 
of this interaction, in support of the notion of state-dependent drug-channel interaction. 
Interestingly, Pless and Ahern discovered that while the cation-π interaction governs UDB by some 
channel inhibitors, it does not play a role in the activity of all inhibitors77. For example, Ranolazine 
does not require the cation-π for UDB, but is still dependent on the presence of F1760, suggesting 
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that there are multiple channel conformations or drug configurations within the pore that can 
impart UDB. 
Though not mutually exclusive, the alternative Guarded Receptor Hypothesis proposes that 
perceived state-dependent binding affinity is in fact the result of transient occlusion of a static 
receptor site that can only be accessed or escaped from certain channel states78. It is curious that 
the cationic form of local anesthetics confers UDB but would be unable to access the binding site 
when applied extracellularly. However, even drugs with high pKa exist as a small fraction of 
neutral drug that can reside in or diffuse across the membrane. Hille proposed that resting-state 
access of lipophilic drugs, which reside for a longer time in the lipid membrane, likely proceeds 
through an intramembrane access pathway70. Larger, less lipophilic molecules likely pass through 
the membrane and require channel openings prior to accessing the binding site75, 79. The time 
constant of UDB is therefore highly dependent on pH80. A series of crystal structures of the 
prokaryotic Nav homolog NavAB revealed for the first time the existence of intramembrane 
fenestrations permeated by membrane lipids and large enough to be traversed by some lipophilic 
drugs19. Interestingly, the size and shape of these fenestrations varied between the structures of 
putatively inactivated and pre-open states, providing a structural basis for state-dependent drug 
access to a central binding site18. 
 
Objective of This Work 
The contents of this work will build on the themes discussed above, and present novel 
observations and models that contribute to our understanding of preferential inhibition of INaL. In 
doing so, this analysis will provide a foundation for patient-specific management of LQT3 and for 
the continued development of novel selective inhibitors of INaL. Chapter 1 identifies the single-
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channel phenotype contributing to INaL in a LQT3 patient with a unique pharmacological response 
to Na+-channel blockade. Our experiments reveal a late reopening phenotype that provides a 
unique opportunity to study mechanisms of selective INaL inhibition in these channels, revealing 
important differences between the pharmacology of Lidocaine and Ranolazine. This chapter also 
demonstrate that these differences result in markedly altered selectivity for INaL in a mutation-
dependent manner. Chapter 2 presents in silico models of drug-channel interactions that 
recapitulate a series of experimental findings and identify important state-dependent binding 
properties that enhance inhibition of INaL by Lidocaine and Ranolazine. In doing so, these models 
demonstrate that the gating kinetics of two different LQT3 phenotypes can account for potentially 
clinically relevant mutation-specific pharmacology. Lastly, Chapter 3 presents the use of unnatural 
amino acids to understand the physical chemical changes that arise during channel inactivation 





















The Long QT Syndrome Type 3 arises in patients with mutations to the cardiac voltage-
gated Na+ channel, Nav1.5. These mutations often result in a significant non-inactivating late 
current during the plateau phase of the ventricular action potential sufficient to delay 
repolarization, prolong the QT interval on an ECG, and increase the risk of ventricular arrhythmia 
and sudden cardiac death. Selective inhibitors of the late current have proven useful in decreasing 
the risk of arrhythmia, however pharmacological intervention often remains unsatisfactory. We 
previously reported the discovery of the F1473C mutation in a patient with severe QT prolongation 
and arrhythmias that were incompletely managed by pharmacology alone. Here we present a 
detailed characterization of the F1473C mutation that reveals abundant channel reopenings as the 
primary mechanism underlying the late current. These reopenings occur frequently enough to 
permit an exploration for the first time of the single channel mechanisms by which two Na+ channel 
inhibitors, Lidocaine and Ranolazine, preferentially inhibit this channel phenotype. Lidocaine and 
Ranolazine reduce the frequency of channel reopenings, while only Ranolazine shortens their 
duration. The differential effect on channel reopenings suggests altered state-dependent drug 
binding, resulting in dramatic mutation-specific pharmacology compared to that of ΔKPQ, a 
naturally occurring mutation with late current caused by rare but prolonged channel bursts. These 
findings reveal an important connection between channel phenotype and susceptibility to 
preferential inhibition of late current that is an important consideration in the continuation of 






In the heart, the voltage-gated Na+ current, INa, is responsible for rapid membrane 
depolarization that leads to the generation of an action potential and the conduction of electrical 
signals to adjacent cells. The activation and inactivation of this current are exquisitely timed to 
enable a transient flux of Na+ ions that contribute most substantially to the first few milliseconds 
of the action potential in a healthy heart9, 81. These currents, carried by the cardiac isoform of the 
voltage-gated Na+-current, Nav1.5, inactivate quickly and almost completely82, thereby 
contributing very little to the membrane potential during the plateau phase of the action potential8. 
However, there exist mutations83, disease states4, 5, and toxins84 that disrupt this inactivation 
process, leading to a marked increase in the sustained depolarizing late current (INaL) that is 
sufficient to prolong the ventricular action potential and increase the risk of ventricular arrhythmia 
and sudden cardiac death8. Consequently, INaL has emerged as an important arrhythmogenic and 
disease-potentiating factor in cardiac conditions such as heart failure and ischemic heart disease49, 
85, 86. However, many questions still remain regarding the molecular etiology of INaL and 
mechanisms by which clinically relevant antiarrhythmic drugs inhibit it.  
  The Long QT Syndrome Type 3 (LQT3) is a congenital disorder of ventricular 
repolarization that is associated with aberrant Na+ flux during the plateau phase of the action 
potential 5, 8, 9. Mutations in SCN5A, the gene encoding Nav1.5, have been shown to cause INaL, 
prolong the ventricular action potential, prolong the QT interval on the clinical ECG, and enhance 
the risk of ventricular arrhythmias and sudden cardiac death in LQT343. These mutations have 
therefore served as a useful experimental model of INaL in heterologous systems1, 13, animal 
models46, 47, and human induced pluripotent stem cell derived cardiomyocytes13, 40, 87 (iPS-CMs) 
and have provided insight into the link between increased Na+ entry and arrhythmia. 
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Several mechanisms of INaL have been characterized in the literature, and involve channel 
gating events with vastly different kinetics. Channel bursting, as best exemplified and first 
identified in the ΔKPQ (1505-1507del) variant, involves the infrequent transition of channels into 
a non-inactivating channel burst state41, 50. These bursts occur in fewer than 0.5% of channels 
during a single depolarization, but often persist for multiple seconds. Importantly, channel bursts 
occur more frequently during bradycardia, resulting in elevated risk of arrhythmia at rest41, 46, 51. 
More recently, a mutation was identified in a patient after arrhythmia occurred during exercise, 
suggesting a non-bursting channel phenotype13. Single-channel analysis revealed a propensity for 
frequent channel reopenings during prolonged depolarizations that were best described as a 
deficiency in channel slow inactivation. Finally, overlap between the voltage-dependent activation 
and inactivation curves can create a window over which channels activate but do not inactivation. 
Mutations which shift inactivation in the depolarizing direction can increase the size of this 
“window current” and the possibility of channels reopening prematurely as the membrane potential 
passes through this range during repolarization. 
Our group previously reported a mutation in a patient with QT-prolongation and poor 
management of arrhythmia with pharmacological intervention, resulting in implantation of an ICD 
at 33 days after birth1, 88. Whole-cell patch clamp experiments in a heterologous expression system1 
and in iPS-CMs87 revealed a range of biophysical changes in channel gating, included marked INaL, 
a depolarizing shift in steady-state inactivation, and a speeding of recovery from inactivation. 
Taken together, the clinical and macroscopic experimental data suggest a unique mechanism of 
INaL generation with altered pharmacological properties. Here we present single-channel evidence 
in support of this hypothesis, and demonstrate that the F1473C mutation results in a mixed 
phenotype of channel bursting and late reopening. Moreover, we find that these reopenings occur 
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more frequently than in previously reported mutations, affording the opportunity to study the 
precise mechanism of preferential inhibition of INaL by two clinically relevant Na+-channel 
inhibitors, Lidocaine and Ranolazine. These inhibitors have different effects on the frequency and 
duration of late reopenings that result in strikingly altered selectivity for inhibition of INaL. Lastly, 
we show that these mechanisms also result in unique mutation-specific differences across channel 
phenotypes, demonstrating that a phenotype-specific approach to pharmacological management is 
important in patients with LQT3. 
 
Methods 
Expression of recombinant Nav1.5 
  WT or mutant Nav1.5 cDNA and b-subunit hb1 cDNA were separately sub-cloned into the 
pcDNA3.1(+) expression vector (Invitrogen). The hb1 vector additionally included the gene for 
CD8, a common and commercially available reporter gene. Equal amounts of a-subunit and b-
subunit totaling 3mg were simultaneously transfected in HEK 293 cells using the Lipofectamine 
2000 reagent (Invitrogen). CD8-positive cells were identified using Dynabeads (Thermo Fisher 
Scientific), and were selected for patching 48 hours after transfection. 
  
Electrophysiology 
  Membrane currents were measured using whole-cell and cell-attached patch clamp 
configurations. All currents were recorded using the Axon 200B amplifier (Axon Instruments) and 
were obtained at room temperature (24°C). Whole cell currents were recorded with pipette 
solutions (mmol): 50 Aspartic acid, 5 ATP-Na2, 60 CsCl,11 EGTA, 10 HEPES, 4.27 CaCl2, 
resulting in a [Ca2+] of 100 nM 1 MgCl2, pH 7.4 adjusted with CsOH.  External solution contained 
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(mmol): 130 NaCl, 5 CsCl, 10 HEPES, 5 glucose, 2 MgCl2. 1.2 CaCl2, pH 7.4 After maintaining 
>1GΩ seal and rupturing the membrane, capacitive currents and series resistance were 
compensated with analog techniques. For all pharmacology experiments, drug trials are control-
matched in the same cell. Following control and drug-exposed experimental trials cells were 
exposed to 50 mM tetrodotoxin (TTX; Abcam) and all whole cell patch clamp results are presented 
as TTX-sensitive currents. 
Cell-attached patch clamp was performed to measure the activity of single ion channels. 
Borosilicate glass pipettes were pulled to a resistance of 5-9 MΩ, and coated with Sylgard (Dow 
Corning) to isolate ambient electrical noise. Pipette solution contained (mmol): 110 NaCl 1 CaCl2, 
5 HEPES, pH 7.4. Bath solution contained (mmol): 140 KCl, 5 HEPES, 1 MGCl2, pH 7.4. After 
obtaining membrane seals of resistance >10GΩ, the number of channels in the patch was estimated 
from the maximal current elicited from a depolarization to -30mV from -120mV. Patches 
containing 1-12 channels were selected for further experimentation. Data was captured at 20kHz 
sampling frequency and filtered online at 5kHz. All experiments were performed using 100ms 
depolarizations to -30mV from -120mV at 1Hz pacing. To test the effects of Na+-channel blocking 
drugs on single channels, we performed control-matched experiments. Channel openings were 
stimulated with 400 consecutive depolarizations under constant perfusion of control bath solution. 
While still applying stimulating pulses, vehicle, 100mM Ranolazine, or 200mM Lidocaine was 
added to the bath perfusion. Following a 2min equilibration period, an additional 400 traces were 
captured as the drug-positive sample under continuous drug perfusion. By comparing control and 
experimental recordings in the same patch we were able to control for inter-patch differences in 





Whole cell currents were analyzed in Clampfit 10 (Molecular Devices, LLC) and are 
reported here as TTX-sensitive currents.  
Single-channel currents were analyzed using Clampfit 10. Baseline correction was 
performed by subtracting the averaged current from at least 10 null sweeps containing zero channel 
openings. As we are primarily interested in the effects of drugs in blocking INaL and overlapping 
channel openings make early events difficult to interpret, single channel event detection was 
performed on the last 90ms of each trace. Single channel openings were identified using Clampfit’s 
Event Detection application, with a minimum event duration of 200µs and a half-amplitude 
detection threshold with unitary current amplitude set to 1.7pA. Mean open duration was 
determined by compiling all channel openings from across patches into an open time histogram, 
which was fit to a single exponential distribution. 
 
Statistics 
Data are presented at mean ± standard error. Statistical significance was determined by a 
Student’s T-test with significance level p<0.05. For comparisons across multiple groups statistical 
significance was determined with a one-way ANOVA with significance level p<0.05, and 
individual comparisons made using a Tukey post-test. Comparisons of channel mean open times 
were tested using Levene’s test for equality of variances. For exponentially distributed data sets, 
the mean and standard deviation are equivalent. A significant difference in variance is therefore 






Ranolazine (lot 114M4743V) and Lidocaine (lot MKBR6002V) were purchased from 
Sigma-Aldrich. Stock solutions were prepared in water at a concentration of 10mM and 100mM, 
respectively. TTX was purchased from Abcam and used at a final concentration of 50µM in water.  
 
Results 
F1473C Causes a Mixed INaL Phenotype. 
As reported previously1, 87, in whole cell patch clamp F1473C results in a large sustained 
INaL during prolonged membrane depolarizations, 0.6% of peak at 200ms, that is significantly 
greater than in WT (Figure 1.1a,b) and a 9mV depolarizing shift in steady-state inactivation1. We 
reasoned that these macroscopic differences were due to mechanistically unique single-channel 
phenotypes and performed cell-attached patch to test this hypothesis. Using trains of 100ms 
depolarizations to -30mV from a holding potential of -120mV at 1Hz pacing frequency, we were 
able to identify two distinct gating abnormalities contributing to INaL. Figures 1.1c and 1.1d depict 
consecutive representative traces from cell-attached patches containing one WT or two F1473C 
channels, respectively. While the WT recordings display very rare ionic currents after the first 
10ms of the pulse, the F1473C recordings display both frequent channel late openings and a 
prolonged burst of channel activity. We only examined the opening events occurring after the first 
10ms of each test pulse and do not differentiate between channel reopenings and primary openings 
that occur after 10ms, as any opening during prolonged times will contribute to INaL. The F1473C 
mutation caused a significant increase in channel reopening per sweep (0.203 ± 0.032 vs 0.012 ± 
0.003; p<0.001) (Figure 1.1E) and a trend towards enhanced channel bursting, as measured by the 
number of bursts per 10,000 channel sweeps (4.93 ± 1.40 vs 1.49± 0.76; p=0.055) (Figure 1.1F). 
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We next asked if the reopenings 
caused by the F1473C mutation were due to 
a transient failure of fast inactivation by 
comparing their mean open duration to that 
of WT. Fits of open dwell time histograms 
to a single exponential distribution revealed 
similar channel mean open times (0.43ms vs 
0.42ms), suggesting that the mutation 
affects only the propensity for channel 
reopening and not the duration of those 
openings (Figure 1.1G and H). These 
findings are consistent with a deficiency in 
slow inactivation but no effect on the fast 
inactivation processes that directly regulate 
channel open duration. 
 
Lidocaine and Ranolazine Inhibit Late 
Reopenings with Differential Effects on 
Open Duration 
Lidocaine and Ranolazine are two 
clinically important Na+-channel inhibitors 
that have been characterized extensively in 
the literature47, 49, 75. Computational models 
Figure 1.1 Single-channel characterization of F1473C. A and 
B) Representative whole cell recordings of WT and F1473C 
Nav1.5 currents. High gain images (insets) depict a substantial 
sustained INaL from F1473C channels. C and D) Consecutive 
representative recordings of cell-attached patches of WT (1 
channel) and F1473C (2 channels) Nav1.5 currents. E) 
Quantification of the number of reopenings per channel per 
sweep after the first 10ms (n=6 patches for WT; n=7 patches for 
F1473C). F) Quantification of the number of sweeps containing 
channel bursts (n=6 patches for WT; n=7 patches for F1473C). 
G and H) Open duration histograms constructed from channel 
openings after the first 10ms of each sweep. Fits to a single 
exponential distribution provided a mean open duration of 
0.42ms for WT and 0.43ms for F1473C. 
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of state-dependent channel affinity based on whole cell experimental data have revealed that 
Lidocaine interacts preferentially with inactivated channels48, 89, while Ranolazine interacts 
preferentially with open channels49, and experiments with unnatural amino acids have revealed 
differences in the chemistry of interaction with the local anesthetic binding site, F176077. Both of 
these mechanisms have proven effective in the selective inhibition of INaL in bursting ΔKPQ mutant 
channels47-49, 90. The robust reopening phenotype of F1473C channels affords the opportunity to 
study the effects of these drugs specifically on those events at the single channel level and to 
determine whether pharmacological differences emerge between bursting and late-reopening 
channels. 
Figure 1.2. Time-dependent changes of late reopenings in F1473C. A) Consecutive representative traces 
of a cell-attached patch containing 3 channels before (left) and after (right) a two minute incubation with 
control vehicle. B) There is no significant change in the frequency of channel reopening between the first 
400 and last 400 sweeps in the same cell (n=7 patches). C) Open duration histograms were constructed from 
channel openings after the first 10ms of each sweep. Fits to a single exponential distribution provided a 
mean open duration of 0.5ms for the first 400 sweeps and 0.52ms for the last 400 sweeps. D) Mean unitary 
current amplitude was reduced by 4.00 ± 1.34% in the last 400 sweeps compared to the first 400 sweeps. 
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We recorded 400 control and 400 drug-containing sweeps from cell attached patches of 
cells exposed to either vehicle (Figure 1.2), 200µM Lidocaine (Figure 1.3) or 100µM Ranolazine 
(Figure 1.4) in the bath solution. In a series of control experiments we tested for time-dependent 
changes in channel reopening frequency, mean open duration, and unitary current amplitude over 
the course of the 15-minute experiment. We observed no time-dependent changes in reopening 
frequency (Figure 1.2b) or duration (Figure 1.2c) between the first 400 and second 400 sweeps. 
We did observe a small 4.00% ± 1.34% (p<0.01) reduction in unitary current amplitude, likely as 
the result of depletion of pipette Na+ and a reduction in the current driving force over the course 
of the experiment (Figure 1.2d). Any drug-induced change in unitary current amplitude in future 
experiments was compared to this 4% time-dependent change.  
Figure 1.3. Lidocaine inhibition of single-channel late openings in F1473C channels. A) Consecutive 
representative traces of a cell-attached patch containing 1 channel before (left) and after (right) application of 
200µM Lidocaine to the bath solution. B) Lidocaine significantly reduced the number of channel openings 
after the first 10ms of each trace (n=3 patches). C) Open duration histograms were constructed from channel 
openings after the first 10ms of each sweep. Fits to a single exponential distribution provided a mean open 
duration of 0.47ms for control and 0.49ms after application of 200µM Lidocaine. D) 200µM Lidocaine has 




Figure 1.3a depicts representative control and 200µM Lidocaine recordings from the same 
patch. After excluding sweeps containing channel bursts, we counted the number of channel 
reopenings after the first 10ms of each trace. Lidocaine reduced the mean number of channel 
reopenings per sweep by 62.4 ± 5.3% (p<0.05) (Figure 1.3b), but had no effect on mean open 
duration (Figure 1.3c) or on unitary current amplitude (Figure 1.3d). We performed a similar set 
of experiments with 100µM Ranolazine. Like Lidocaine, Ranolazine caused 33.2 ± 8.6% (p<0.01) 
reduction in reopenings (Figure 1.4b). However, unlike Lidocaine, Ranolazine reduced the mean 
open duration by 27.3% (p<0.001) (Figure 1.4c), consistent with a proposed interaction with open 
channels. Ranolazine had no effect on unitary current amplitude (Figure 1.4d). As posited from 
whole cell48, 49, 89 and computational studies, our results confirm an important difference between 
Figure 1.4. Ranolazine inhibition of single-channel late openings in F1473C channels. A) Consecutive 
representative traces of a cell-attached patch containing 1 channel before (left) and after (right) application of 
100µM Ranolazine to the bath solution. B) Ranolazine significantly reduced the number of channel openings 
after the first 10ms of each trace (n=9 patches). C) Ranolazine reduced the mean open duration by 27.3%. 
Open duration histograms were constructed from channel openings after the first 10ms of each sweep. Fits to 
a single exponential distribution provided a mean open duration of 0.55ms for control and 0.40ms after 





Lidocaine and Ranolazine: Ranolazine interacts with open channels to alter the duration of channel 
openings, whereas Lidocaine does not. The ability of Lidocaine to inhibit INaL driven by late 
reopenings is solely through a reduction in the number of these events. 
Distinct Kinetics of F1473C Inactivation 
Figure 1.5 compares the inactivation properties of F1473C to the canonical LQT3 mutation 
ΔKPQ. The kinetics of F1473C inactivation are slower than in ΔKPQ during a 200ms depolarizing 
pulse to -10mV from -100mV (Figure 1.5a). This results in a time dependent INaL that decays 
gradually and is consistent with impairment of channel slow inactivation observed in other 
channels with a late opening phenotype13. By contrast the kinetics of INaL in ΔKPQ are rather time-
independent, a hallmark of persistent channel bursting that provides sustained current for multiple 
seconds41, 50. At 200ms, INaL from F1473C was similar to ΔKPQ despite these altered kinetics 
(Figure 1.5b). We compared the frequency of single-channel bursting in these mutations, and 
observed a dramatically higher probability of channel bursting in ΔKPQ channels compared to 
WT (p<0.01) and F1473C (p<0.05) (Figure 1.5c). The mechanisms underlying INaL in these two 
mutations are therefore quite different. We next sought to explore the effects that these differences 
might have on state-dependent channel block by Lidocaine and Ranolazine. 
Figure 1.5. Kinetic differences between F1473C and ∆KPQ. A) Representative whole cell recordings of 
F1473C (gray) and ∆KPQ (black) during a 200ms pulse to -10mV from -100mV at 0.2Hz pacing. High gain 
images (inset) depict slowed inactivation kinetics of F1473C and time-independent INaL of ∆KPQ. B) F1473C 
and ∆KPQ have similar INaL at 200ms. C) Single ∆KPQ (n=3 patches) channels burst more frequently than 





Figure 1.6. Mutation-specific pharmacology of Lidocaine. A) Representative recordings of ∆KPQ and 
F1473C currents before and after application of 200µM Lidocaine at low gain and high gain (insets). B) Block 
of peak and late current of ∆KPQ (n=7 cells) and F1473C (n=6 cells) channels by 200µM Lidocaine. Note the 
enhanced selectivity for INaL in F1473C. C) Kinetics of Lidocaine inhibition of F1473C and ∆KPQ currents 
during a single 100ms depolarization. Traces are averaged across all cells. 
	
Figure 1.7. Mutation-specific pharmacology of Ranolazine. A) Representative recordings of ∆KPQ and 
F1473C currents before and after application of 100µM Ranolazine at low gain and high gain (insets). B) 
Block of peak and late current of ∆KPQ (n=5 cells) and F1473C (n=6 cells) channels by 100µM Ranolazine. 
C) Kinetics of Ranolazine inhibition of F1473C and ∆KPQ currents during a single 100ms depolarization. 




Single-Channel Phenotypes Underlie Mutation-Specific Pharmacology 
Figures 1.6 and 1.7 illustrate the effects of 200µM Lidocaine and 100µM Ranolazine on 
the two LQT3 mutant channels at the whole cell level. Both drugs preferentially inhibit INaL in both 
mutations, but the degree of selectivity varies widely in a mutation- and drug-dependent manner. 
Lidocaine is a far less potent inhibitor of peak INa in F1473C compared to ΔKPQ (9.70 ± 0.81% 
vs 33.81± 1.15%, p<0.001), while the effect on INaL is similar (60.35 ± 6.30% vs 63.62 ± 5.55%, 
p=0.70) (Figure 6b). Conversely, Ranolazine is a more potent inhibitor of both peak INa (23.85 ± 
1.28% vs 44.28 ± 2.74%, p<0.001) and INaL (39.38 ± 5.16% vs 72.58 ± 3.37%, p<0.001) in ΔKPQ 
channels (Figure 1.7b). 
We reasoned that differences in block of INa and INaL were likely reflective of differences 
in the kinetics of current inhibition that are not captured in our analysis of peak and 100ms time 
points. To investigate this hypothesis, we analyzed the percentage of current blocked by drug over 
the course of a full 100ms depolarization. 200µM Lidocaine showed dramatically different kinetic 
profiles for inhibition of the two mutant channels (Figure 1.6c). Block of F1473C developed 
continually over the course of a depolarizing step, whereas block of ΔKPQ developed rapidly and 
reached steady-state in approximately 20ms. These kinetic profiles reflect the time courses of 
channel inactivation, where F1473C INaL decays slowly and ΔKPQ INaL reaches a plateau more 
quickly.  
The ability of channel inhibition to reflect the underlying current kinetics is absent in block 
of INaL by 100µM Ranolazine, which blocked with similar kinetics but altered amplitude in F1473C 
and ΔKPQ channels (Figure 1.7c). Ranolazine binding therefore reflects a kinetic scheme that is 
insensitive to changes in slow inactivation. These findings are consistent with our analysis of 
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Lidocaine and Ranolazine inhibition of single-channels, and confirm that these two inhibitors 
interact with the channel in unique ways. 
 
Discussion 
F1473C: A Complex LQT3 phenotype 
The seminal study reporting the macroscopic function of the LQT3-associated mutation 
F1473C identified several pathological changes in channel gating, including a depolarizing shift 
in steady-state inactivation, a speeding of recovery from inactivation, and a substantial INaL1. Here 
we present for the first time a detailed single-channel characterization of INaL in this mutation. 
F1473C causes a trending increase in the probability of channel bursting and a more dramatic 
increase in the probability of late reopening. In our experiments, a single channel will open after 
the first 10ms of a 100ms pulse in 20% of the depolarizing sweeps, 20-fold more often than WT 
channels. We found that these reopenings have a mean duration that is very similar to the rare 
reopenings in WT channels in our experiments and to the WT mean open duration reported by 
others13, 54, 91. The ability of F1473C channels to reopen without a change in open duration suggests 
that the mutation alters channel slow inactivation to allow for reopenings, but has no effect on the 
kinetics of fast inactivation13. This is a striking finding given the location of F1473C in the linker 
between domains III and IV of Nav1.5, which is a known molecular determinant of fast 
inactivation20, 21.  
While F1473C channel bursting is slightly enhanced compared to WT, it represents only a 
fraction of the bursting activity observed in ΔKPQ channels. However, this small amount of 
bursting is sufficient to account for the previously reported preferential reduction in INaL with faster 
pacing frequency87 – a hallmark of channel bursting41. Taken together, our experiments provide a 
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potential connection between the single-channel behavior, the experimentally observed rate-
dependence, and the severity of disease caused by the F1473C mutation. Increased pacing relieves 
the burden of a small degree of channel bursting but does not remedy, and may even unmask, the 
effects of channel reopening. 
 
The Molecular Determinants of INaL Inhibition by Lidocaine and Ranolazine 
Several studies have used experimental and computational approaches to investigate the 
effects of local anesthetic drugs on bursting channels46-49, 90. Lidocaine and Ranolazine, in 
particular, have served as model cases for two general mechanisms of channel interaction. Based 
on its ability to dramatically shift channel availability in the hyperpolarizing direction, slow 
recovery from inactivation, and allosterically modulate a voltage-sensor important in channel 
inactivation74,92, Lidocaine is the archetypical local anesthetic with selective affinity for 
inactivated channels. More recently, the effects of Ranolazine on ΔKPQ have been interpreted as 
preferential inhibition of open channels because of its small effect on channel availability49, 93. 
We sought to understand the effects that these putative mechanisms would have on channel 
late reopening. The frequent reopenings caused by the F1473C mutation provided an opportunity 
to study the single channel block of these events in a way not previously possible. We found that 
while both drugs were able to reduce the frequency with which late openings occur, only 
Ranolazine had an effect on channel mean open time. Coupled with a smaller impact on steady-
state inactivation and unique kinetics of inhibition, these results imply important differences in the 
interaction of these drugs with the local anesthetic binding site that influence selective inhibition 
of INaL in these channels. 
34	
	
Both Lidocaine and Ranolazine rely heavily on F1760, the local anesthetic binding site, for 
use-dependent block and INaL inhibition47, 67, 68. Access to the local anesthetic binding site, which 
resides within the central conducting pore67, 68, is limited by channel state and by the chemistry of 
the ligand. Hydrophilic or charged drugs must access this site through the open aqueous pore. 
Lipophilic drugs, which reside for longer times within the plasma membrane, may access the 
binding site via a lipophilic route, predicted first by Bertil Hille70 and identified more recently in 
crystal structures of the prokaryotic voltage-gated Na+-channel homolog NavAB18, 19. Interestingly, 
Ranolazine is a derivative of Lidocaine and contains a Lidocaine moiety, similar pKa, and similar 
partition coefficient77, 94. It is therefore surprising that the effects on channel reopening are so 
different. However, Ranolazine is larger in size, likely limiting its ability to access the lipophilic 
pathway in non-conducting channels and altering its orientation in the pore with respect to F1760. 
In fact, Pless et al identified a critical cation-𝛑 interaction that governs use-dependent block by 
Lidocaine but not Ranolazine, indicating important differences in the chemistry of drug binding. 
Taken together, these experiments demonstrate that derivatives of classical local anesthetic drugs 
may display markedly different pharmacological activity that alter the kinetics and magnitude of 
channel inhibition. Understanding the chemical underpinnings of drug access and binding is a 
critical step in the design of therapeutic programs for patients with INaL-associated cardiac disease. 
 
Impact of Channel Phenotype on Preferential Inhibition of INaL 
We reasoned that because F1473C and ΔKPQ mutations alter channel gating in unique 
ways, their susceptibility to state-dependent channel inhibition would also vary. Lidocaine reduced 
INaL in both mutations by a similar amount. Our single channel experiments revealed that Lidocaine 
inhibits INaL solely by reducing the frequency of late events. In agreement with this notion, a 
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previous study of the inhibition of single ΔKPQ channels revealed that Lidocaine reduced the 
frequency of channel bursts without any effect on their duration90. Because the F1473C reopenings 
result in a time-varying INaL and the ΔKPQ bursts cause a time-independent INaL, normalization of 
currents by elimination of these phenotypes would produce unique kinetics of block. In fact, we 
observed a slower time course of inhibition of F1473C currents than ΔKPQ. The depolarized 
channel availability and more rapid recovery from inactivation of F1473C channels results in 
diminished peak current block and enhanced selectivity for INaL. While the qualitative effect on 
late reopenings and bursts is similar, the properties of the channels themselves influence the 
kinetics and selectivity of block. 
Ranolazine, on the other hand, does not display mutation-dependent kinetics. The time 
course of block in the two mutations is similar, but the magnitude of inhibition of ΔKPQ channels 
is greater. The reduction in mean open duration caused by Ranolazine requires that the drug binds 
very rapidly to open channels. It is therefore likely that the kinetics of INaL inhibition are governed 
predominantly by the rapid binding of drug to open channels, with less influence from the kinetics 
of inactivation. However, the bursting that causes INaL in ΔKPQ and contributes a fraction of INaL 
in F1473C has longer mean open duration than late reopenings or early transient openings, 
providing more time for drug to bind and an increased magnitude and selectivity for INaL derived 
from bursts. These findings suggest that a shortening of mean open time by some local anesthetics 
is detrimental to selective inhibition of reopenings, but effective at targeting channel bursts. 
Pharmacological intervention in patients with LQT3 is already complicated by the potential 
for off-target effects on other ion channels, which are influenced by genetic diversity among 
patients1, 87. Our results highlighting additional heterogeneity within INaL itself enhance the need 
for an understanding of specific mechanisms of selective inhibition. The findings presented here 
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imply that the effect of inhibitors on the frequency and duration of late events can contribute to 
their selectivity for INaL in a mutation-dependent manner. By examining these mutations and drugs, 
which serve as general models for the diverse pathology and pharmacology of LQT3, we can begin 
to understand the specific drug-channel interactions that impart preferential inhibition of INaL. In 
Chapter 2 we present a series of computational models of LQT3 channel function that extend the 
quantitative connection between impaired channel gating, state-dependent drug binding, and 
mutation-specific pharmacology of local anesthetic drugs with unique chemical properties. These 
findings have important implications in the patient-specific management of LQT3, and an 
understanding of the molecular etiology of INaL for a given mutation or disease state may inform 


























Chapter 2: Computational modeling of state-dependent drug binding in mutation-specific 





The late sodium current has emerged as an important factor in the pathogenesis of several 
cardiovascular ailments, sparking a renewed interest in the antiarrhythmic mechanisms of local 
anesthetic inhibition of the cardiac voltage-gated Na+ channel, Nav1.5. Patients with heritable INaL 
arising from mutations in Nav1.5 and the congenital Long QT Syndrome Type 3 (LQT3), have 
demonstrated some clinical benefit to pharmacological intervention, but incomplete INaL selectivity 
raises the risk of impaired cardiac conduction and drug-induced arrhythmia. A more detailed 
understanding of the properties that impart selective inhibition of INaL by local anesthetics is 
therefore desirable. Kinetic models of ion channel function are useful in developing testable 
hypotheses from dynamic systems, such as channel gating and state-dependent drug binding. This 
chapter presents a computational approach to unraveling the mechanisms that underlie mutation-
specific inhibition of different varieties of INaL. First, we develop an updated kinetic model of WT 
channel gating based on a new series of kinetic constrains that define transitions important in the 
population of high affinity channel states. Only slight deviations from the WT model generate 
virtual LQT3 mutant channels with distinct gating phenotypes, such as the F1473C and ΔKPQ 
mutations characterized in Chapter 1. The disease models then serve as the foundation for a 
characterization of the state-dependent drug-channel interactions that impart mutation-specific 
inhibition of INaL by Lidocaine and Ranolazine. The models suggest that much of the mutation-
specific pharmacology can be attributed to differences in channel gating kinetics that result in 
unique distributions of high affinity channel states. Finally, this chapter presents proof of concept 
for the in silico screening of patient-specific responses to local anesthetics with different 





In silico pharmacology holds enormous value in providing a platform for examining 
competing theories for mechanisms of drug binding and in predicting clinically relevant outputs 
from complex biological systems. Cardiology therapeutics is a particularly well-suited area for the 
employment of virtual drug discovery because rhythmic contraction is driven by the integration of 
numerous ionic currents and chemical signals. One particular aspect of cardiac physiology that has 
gained a growing interest is the pathological late Na+-current (INaL) that has been observed in 
multiple disease states to contribute to action potential prolongation and arrhythmogenesis4, 5, 59, 
95. Computational analysis has been used repeatedly to predict the pathological effects of INaL and 
to demonstrate the potential clinical benefit of selective INaL inhibition across a range of cardiac 
disorders11, 41, 42, 46, 48, 49, 85, 86.  
To explore altered Na+ channel gating, kinetic models have evolved from simple Hodgkin-
Huxley models to more complex multi-state models that attempt to capture the functional 
properties of the channel15, 41, 49, 96, 97. In these newer models, physiologically relevant 
conformational changes and functional properties are represented by voltage-dependent transitions 
between states in a hidden Markov chain98. By altering the rates of these transitions the models are 
capable of reproducing many aspects of the pathophysiology associated with the Long QT 
Syndrome Type 3 (LQT3)13, 41, Brugada Syndrome97, 99, and heart failure11. Additionally, these 
models have proven useful in describing the state-dependent binding mechanisms of clinically 
relevant Na+-channel inhibitors and extrapolating those properties into effects on action potentials, 
tissue segments, and ultimately simulated ECGs11, 49, 85. This chapter expands upon that body of 
work to describe the fundamental underpinnings of mutation-specific pharmacology in LQT3.  
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LQT3 arises from mutations in the cardiac isoform of the voltage-gated Na+-channel a-
subunit, Nav1.5, that impair channel inactivation resulting in aberrant late Na+ current (INaL), 
prolonging the ventricular action potential and consequently prolonging the QT-interval on the 
surface ECG10. Data presented in Chapter 1 characterized the LQT3-associated mutation F1473C 
at the single channel level. This mutation was discovered in a patient with QT prolongation that 
was incompletely controlled by pharmacological intervention1, 88. Our experiments demonstrate 
that INaL from this mutation is functionally distinct from INaL in the canonical LQT3 mutation 
ΔKPQ, and displays a markedly different response to inhibition by Lidocaine and Ranolazine, two 
drugs that have been used clinically to treat LQT3. There exist two possible explanations for these 
differences in pharmacology. First, F1473C and ΔKPQ alter channel gating in unique ways, and 
Lidocaine and Ranolazine are known to interact with Nav1.5 in a highly state-dependent manner. 
It is therefore possible that the altered distribution of channel states in these mutations will result 
in differential drug-channel affinity when averaged across all states. Alternatively, it is possible 
that these mutations, which reside in the DIII/DIV linker, part of  the channel inactivation 
machinery21, cause an allosteric disruption of the drug binding site and mutation-specific 
modulation of binding affinity. Such a conjecture is difficult to test with our current level of 
structural understanding in these channels, but in silico drug screening allows for a prediction of 
the pharmacological properties important in inhibition of INaL. 
This Chapter first presents an updated model of cardiac INa gating that accounts for 
important inactivation properties not reproduced in existing models. These inactivation properties 
are impaired in the presence of LQT3-associated channel mutations in a mutation-dependent 
manner, and can play a role in preferential inhibition of INaL. We use this model of channel gating 
as the foundation for the simulation of INaL generated by the LQT3 mutations F1473C and ΔKPQ. 
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The unique gating properties of these mutant channels are hypothesized to result in mutation-
specific pharmacological profiles. Our models suggest, for the first time, that changes in channel 
gating kinetics alone are sufficient to account for most of the mutation-specific pharmacology of 
INaL by both open- and inactivated-channel blockers. Moreover, these models confirm previously 
proposed differences in the state-dependent binding affinities of Lidocaine and Ranolazine that 
contribute to alternative modalities of selective INaL inhibition. These findings provide proof of 
concept for screening of local anesthetic activity based on channel phenotype and the development 
of patient-specific therapeutic regimens in the treatment of cardiac arrhythmia. 
 
Methods 
Expressions of recombinant Nav1.5 
WT or mutant Nav1.5 cDNA and hb1 (human beta1 subunit) cDNA were separately sub-
cloned into the pcDNA3.1(+) expression vector (Invitrogen). The hb1 vector additionally included 
the gene encoding CD8, a common and commercially available reporter gene. Equal amounts of 
 a-subunit and b-subunit totaling 3mg were simultaneously transfected in HEK 293 cells using the 
Lipofectamine 2000 reagent (Invitrogen). CD8-positive cells were identified using Dynabeads 
(Thermo Fisher Scientific), and were selected for experiments 48 hours after transfection. 
 
Electrophysiology 
Membrane currents were measured using whole-cell and cell-attached patch clamp 
configurations. All currents were recorded using the Axon 200B amplifier (Axon Instruments) and 
were obtained at room temperature (24°C). Whole cell currents were recorded with pipette 
solutions (mmol): 50 Aspartic acid, 5 ATP-Na2, 60 CsCl,11 EGTA, 10 HEPES, 4.27 CaCl2, 1 
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MgCl2. External solution contained: 130 NaCl, 5 CsCl, 10 HEPES, 5 glucose, 2 MgCl2. 1.2 CaCl2. 
After maintaining >1GΩ seal and rupturing the membrane, capacitive currents and series 
resistance were compensated with analog techniques. For all pharmacology experiments, drug 
trials are control-matched in the same cell. Following control and drug-exposed experimental trials 
cells were exposed to 50 mM tetrodotoxin (TTX) and all whole cell patch clamp results are 
presented as TTX-sensitive currents. 
Cell-attached experiments used to examine the function and pharmacology of single ion 
channels are presented in Chapter 1. 
 
Computational Modeling of WT and Mutant Nav1.5 
We developed a Markov model for Wild Type Nav1.5 gating that is based on the Clancy-
Rudy model41. Our model contains 14 distinct drug-free channel states and 14 parallel drug-bound 
states with time-varying occupancy represented as a system of ordinary differential equations 
(Figure 2.1a). The model contains several closed states (Cx), closed-inactivated states (ICx), one 
open state (O), one fast inactivated state (IF), two sequential slow inactivated states (IS1 and IS2), 
burst mode closed states (BCx), and one burst mode open state (BO) (Figure 2.1). Voltage-
dependent rate constants are described by Eyring Rate Theory: 
𝑘 = 𝑘$𝑒&'(/*+ 
where k is the rate constant, k0 is the rate constant at 0mV, q is the charge movement across the 
membrane, V is the membrane potential, R is the gas constant, and T is temperature16. k0 and q 
were optimized using a least squares error minimization96 with iterative parameter perturbations 
performed using a simulated annealing algorithm100. Constraining data included voltage-
dependent conductance, steady state inactivation, fast-inactivation kinetics, recovery from 
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inactivation, and closed-inactivation kinetics. Parameter optimization and simulations were 
encoded in MATLAB. Optimized voltage-dependent rate constants are described in Table 2.1.  
Time-varying state occupancies were simulated by integrating the system of ordinary 
differential equations over time, and INa was calculated as: 
𝐼-. = 𝐺-. ∗ 𝑃 𝑂 + 	𝑃 𝐵𝑂 ∗ (𝑉 − 𝐸-.) 
where GNa is the Na+ conductance, P(O) and P(BO) are the fractional occupancies of burst and 
burst open states, V is membrane potential, and ENa is Nernst equilibrium potential for Na+. 
Single channel simulations are performed stochastically by calculating a dwell time, T, as: 
𝑇 = − ln 𝑟/ 𝛼@A 
where r is a random number on the open interval (0,1), and 𝛼@A	are the transitions rates from the 
current state (j) into neighboring states (k)13. Following the dwell time in state j, the transition to 




LQT3 mutant channel function was simulated after manual modification of transitions rates, which 
are summarized in Table 2.2. Three classes of rate adjustments were performed to capture the 
range of observed mutant phenotypes: shifts in steady-state availability, channel bursting, and 
channel late reopening (Figure 2.1). F1473C rates were modified based on single channel and 
whole cell data reported in Chapter 1 and in the literature1. Channel bursting rates for ΔKPQ were 




Lidocaine and Ranolazine Models 
Models of Lidocaine and Ranolazine binding to LQT3 mutant channels were constructed 
by the addition of 14 parallel channel states to the drug-free model (Figure 2.2a). Each drug-free 
channel state is capable of interacting with drug and, with the exception of accommodations for 
microscopic reversibility (Figure 2.2b), transitions between drug-bound states occur with the same 
rate constants as drug-free channels. Drug-channel interactions are defined by a second order rate 
constant (kdiff) and binding affinity (Kd), where the on-rate (kon) and off-rate (koff) constants are 
calculated as follows: 
kon = kdiff*[Drug] 
koff = kdiff*Kd 
The models presented here were constructed with six free parameters: kdiff-Lipophilic, kdiff-Hydrophilic, 
Kd-closed, Kd-inactivated, Kd-slow inactivated, and Kd-open. Hydrophilic and lipophilic rate constants allow for 
Figure 2.1 WT and Mutant Nav1.5 Channel Gating. WT channel gating is represented as the transition 
between closed states (C), inactivated states (Ix), burst states (Bx) and an open state (O). The three mutation-
induced changes in channel gating – shifts in stead state inactivation (green), increases in channel bursting 






the distinction between drug reaching its binding site through the open hydrophilic pore or through 
intramembrane pathways putatively identified in crystal structures of homologous prokaryotic 
channels18, 19, 70. These rate constants are reflective of state-dependent binding site access, and 
capture effects of pKa, charge, size, and partition coefficient.  
State-dependent binding affinities allow for the allosteric regulation of channel states by 
drug, as posited by the Modulated Receptor Hypothesis70 and detailed in Figure 2.2b. Parameters 
were optimized using a least squares error minimization with iterative parameter perturbations 
calculated by a simulated annealing algorithm as described above.  
 
Action Potential Clamp Simulations 
In addition to simulating currents elicited by square voltage pulses and standard 
experimental voltage protocols, we also simulated the effect of mutations on INa during voltage 
waveforms of ventricular myocytes. To produce the voltage waveform, current clamp simulations 
of the O’Hara-Rudy epicardial myocyte model101 were performed at 1Hz pacing to steady-state 
(>100 beats). The resulting voltage output was then used as the input in whole cell voltage-clamp 
simulations of our Nav1.5 channel model. State transitions and ionic current were calculated from 










The sensitivity of the models to variations in each of the six drug-binding parameters was 
tested using a sensitivity analysis. For each parameter, twenty iterations of random variation were 
performed to create novel virtual drugs that differ in one parameter from the optimized models96. 
After modifying a parameter by a random percentage between 50% and 150% of its optimized 
value, action potential clamp simulations were run and model output calculated as the ratio of INaL 
inhibition to peak INa inhibition. This ratio was plotted against the percent adjustment of the input 
parameter and fit to a linear relationship.  
Figure 2.2 State-dependent binding of local anesthetics. A) Drug may bind to any channel state, 
including bursting channels (red). Drug-bound channels may transition between adjacent states as in the 
drug free state, but the distribution of states is modulated by microscopic reversibility. B) Example of state-
dependent drug access and binding that results in allosteric modulation of gating. Open state drug binding 
proceeds through the hydrophilic access pathway, but binding to non-conducting inactivated channels 
requires access through the lipophilic pathway. Differences in binding affinity of the two states without 
accommodation violates microscopic reversibility, which must be accounted for by the inclusion of factor 
L. When KdI<KdO and factor L>1, inactivated state block is stronger and L drives the equilibrium towards 
inactivated states. When KdO<KdI open state block is stronger and L<1, pulling the equilibrium towards 
open states. Microscopic reversibility therefore serves as a mathematical representation of allosteric gating 





Refinement of closed-inactivation kinetics in a model of Nav1.5 gating. 
To begin to understand the kinetics of pharmacological inhibition of INaL, there are a series 
of properties that models of channel gating must approximate. Certain gating transitions, such as 
the kinetics of closed channel inactivation and the kinetics of slow inactivation, regulate the 
population of channel states postulated to have high affinity for local anesthetic drugs75, 89, 102. We 
developed a new experimental protocol to assess the kinetics and voltage-dependence of these 
transitions, and found that previous models which were not constrained with similar data 
inadequately reproduced our findings. We therefore expanded on this previous work and 
parameterized a new model of Nav1.5 gating using these experimental protocols as additional 
constraints.  
The structural scheme of the model is based on that of the Clancy-Rudy model41 (Figure 
2.3a), developed previously to described the voltage-dependent properties of WT and some LQT3 
mutant channels. We assumed that the voltage-dependent transitions between states are defined by 
Eyring Rate Theory, as described above, resulting in voltage-dependent currents depicted in Figure 
2.3b. This formulation allowed each voltage-dependent rate constant to have a unique value for k0 
and q, which we optimized with a series of experimental data sets including the single-channel 
mean open duration (0.5ms), the voltage dependence of activation and steady-state inactivation 
(Figure 2.3C), the kinetics of fast inactivation (Figure 2.3D), and recovery from 50 and 500ms 
depolarizations to -10mV (Figure 2.3E), as described previously96. Including recovery from 
inactivation after conditioning pulses of two durations allows the calibration of the transition 
between IS1 and IS2 – a transition not readily detectable in other protocols - based on the relative 




Figure 2.3. Model of WT Nav1.5 Channel Gating. A) Schematic of model structure. The Markov channel 
model contains three closed (Cx), an open (O), three closed inactivated (ICx), a fast (IF) and two slow 
(ISx) inactivated states. Additionally, the low probability Burst Mode (BCx, BO) transitions are permitted 
from Cx and O states. B) Simulated currents obtained from a holding potential of -100mV to test potentials 
ranging from -60mV to +10mV. C) Voltage dependent activation (n=5) and steady state inactivation (n=12) 
experiments (symbol) and simulations (lines). D) The voltage-dependence of fast inactivation is measured 
as the t1/2 of decay from peak (n=4). E) Recovery from inactivation following a 50ms (n=6) and 500ms 
(n=4) conditioning pulse to -10mV. F) The voltage-dependent kinetics of closed-inactivation (n=9). 
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In addition, we included a new set of experimental data describing the time course of 
transition from closed states into closed-inactivated states. By including this data set, the model is 
able to approximate both the steady-state properties and kinetics of channel availability. In this set 
of experiments, we measured the peak Na+-current during a test pulse to -10mV after a sub-
activation threshold conditioning pulse for varying durations (Figure 2.3F). As the conditioning 
duration increases more channels inactivate and the peak current during the test pulse is 
diminished. Plotted against the conditioning pulse duration, the decline in peak current fit well to 
a single exponential decay yielding voltage dependent time constants of 69.7 ± 8.5ms (-65mV), 
55.2 ± 6.4ms (-60mV), 37.1 ± 3.0ms (-55mV), 23.8 ± 2.5ms (-50mV). With this added constraint, 
we optimized a set of voltage-dependent rates that account for these important channel functions 
(Table 2.1). 
 
Table 2.1. Voltage-Dependent Transition Rate Constants of WT Nav1.5  
Transition Rate Constants (ms-1) 
C1->C2; IC1->IC2 a11 = 17.89e(v/100) 
C2->C3; IC2->IC3 a12 = 92.78e(v/13.53) 
C3->O a13 = 19.24e(v/19.89) 
C2->C1; IC2->IC1 b11 = 0.45e(-v/14.89) 
C3->C2; IC3->IC2 b12 = 0.96e(-v/14.22) 
O->C3; IF->IC3 b13 = 0.21e(-v/25.70) 
Cx->ICx a3 = 0.015e(v/305.81) 
ICx->Cx b3 = (2.35E-6)e(-v/8.33) 
O->IF a2 = 1.41e(v/578) 
IF->O b2 = 0.003e(-v/1000) 
IF->IS1 a4 = 0.077e(v/1000) 
IS1->IF b4 = (1.94E-4)e(-v/14.69) 
IS1->IS2 a5 = 0.008e(v/1000) 
IS2->IS1 b5 = 0.005e(-v/1000) 
IC3->IF a13*(a2*b3)/(a3*b2) 
Cx->BCx; O->BO µ1 = 2E-7 





Effect of mutations on channel gating 
Chapter 1 presented experimental evidence that the gain of function pathology that results 
from the F1473C and DKPQ mutations are the result of unique current signatures. DKPQ causes 
infrequent but prolonged periods of channel bursting50 and a time-independent INaL. F1473C, on 
the other hand, caused a nominal increase in channel bursting compared to WT, but a significant 
increase in the frequency of dispersed late reopenings, time-varying INaL, and a depolarizing shift 
in steady-state inactivation. We hypothesize that these gating deficiencies produce distinct 
responses to INaL inhibition, and therefore sought to construct models of channel gating that 
reproduce the main features of these mutations to serve as the basis for models of selective INaL 
inhibition. 
Table 2.2. Rate Modifications of Mutant Nav1.5 
 Modification Effect 
 
F1473C 
b3 = b3*10 Depolarizing shift in SSI; faster recovery 
a4 = a4/30  Increase in late reopening frequency and INaL 
µ1 = µ1*2 Slight increase in burst frequency and INaL 
DKPQ µ1 = 1.84*10-6 Increase burst frequency and INaL 
 
To model the effects of F1473C and DKPQ mutations on channel gating we manually 
manipulated individual rate constants based on experimental data obtained by us and others (Table 
2.2)1, 87. Figures 2.4a and 2.4b display simulated whole cell currents from DKPQ and F1473C 
models, respectively. Note the varying kinetics of INaL in these two models (inset), where the INaL 
continues to decay at prolonged times in the F1474C model, but is relatively time-independent in 
DKPQ. Our experiments analyzing the single channel properties of F1473C revealed that the 
mutation did not significantly alter the channel mean open duration from WT, so this time-
dependent deficiency in inactivation is likely the result of impaired slow inactivation. We therefore 
simulated F1473C INaL by reducing a4, the rate governing the transition from fast inactivation to 
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slow inactivation. Alternatively, DKPQ INaL results from a modal shift in which a slow gating 
transition regulates entry of channels into a bursting mode that lacks inactivation41. Transitions 
into and out of this gating mode are several orders of magnitude slower than transitions that govern 
transitions in the background mode. 
We further refined these rate manipulations with considerations from our single channel 
experiments. Unlike the simulations of whole cell currents, simulations of single channel behavior 
Figure 2.4. Whole cell and single channel properties of simulated LQT3 Nav1.5. A) Low and high (inset) 
gain currents from DKPQ. The kinetics of INaL are independent of time. B) Low and high (inset) gain currents 
fromF1473C. INaL decreases gradually over time. C) Simulated steady-state inactivation(Liu, Clancy et al. 2003, 
Bankston, Yue et al. 2007). F1473C causes a depolarizing shift in channel availability. D) Simulated recovery 
from fast and slow inactivation(Bankston, Yue et al. 2007). E) Representative simulated currents from a single 
DKPQ channel containing two bursting sweeps. F) Representative simulated currents from a single F1473C 
channel containing one bursting sweep and several dispersed late reopenings. G) Mean number of bursts per 
10,000 sweeps calculated from the independent simulation of 10 sets of 2,000 sweeps. H) Mean number of late 
openings per 100 sweeps after the first 10ms of a sweep using the same method as above.  
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are stochastic and non-deterministic. We therefore approximated our experimental conditions by 
simulating ten sets of 2,000 sweeps from a holding potential of -120mV to a test pulse voltage of 
-30mV for 100ms at 1Hz. Figure 2.4c and d display simulated single channel recordings of DKPQ 
and F1473C channels. The modification of a4 that represented a deficiency in slow inactivation 
resulted in a prolongation of the mean occupancy duration of IF, and therefore a prolonged period 
over which channels may reopen from this state. The slow decay of INaL in this mutation is therefore 
consistent with an increased contribution from late reopenings (Figure 2.4e).  
In addition to reopenings, we accounted for a trend in increased F1473C channel bursting 
by doubling the rate of transition from the background mode to the burst gating mode (µ1), 
resulting in a slight increase in both the frequency of channel bursting and INaL in line with our 
experiments (Figure 2.4f). The DKPQ mutation has classically been modeled with an increase in 
burst frequency as the sole source of increased INaL42, 46, 48, 49. With only a very slight modification 
in the rates of DKPQ bursting reported previously49, we were also able to recapitulate the single 
channel and whole cell pathological gating in these channels. We increased the previously reported 
rate constant of transition into the burst gating mode from 1.44*10-6ms-1 to 1.84*10-6ms-1 because 
the peak Popen of our model was slightly higher than in previous models. Compared to WT (2*10-
7ms-1) and F1473C (4*10-7ms-1), these rates suggest a 9.2 and 4.6-fold greater frequency of 
bursting, respectively, in line with our experimental observations (Chapter 1). 
The seminal study describing the whole cell properties of F1473C revealed a dramatic 
depolarizing shift in steady-state inactivation and a speeding of recovery from inactivation1. While 
slowing a4 contributed some speeding of recovery, the transition from ICx to Cx is rate-limiting 
in our model and controls steady-state channel availability. We therefore accounted for both the 
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shift in channel availability (Figure 2.4g) and the speeding of recovery from inactivation (Figure 
2.4h) by increasing b3 in the F1473C model. 
 
Effect of channel gating on inhibition of INaL  
  The magnitude and kinetics of inhibition of F1473C and DKPQ currents by the clinically 
relevant Na+-channel inhibitors Lidocaine and Ranolazine occur in a highly mutation-dependent 
manner (Chapter 1). There exist two possible explanations for these differences that are difficult 
to test experimentally: the mutations alter the physical chemical association of drug and channel 
to alter binding affinity, or alternatively, the mutation-induced changes in channel gating result in 
an altered distribution of high affinity channel states. Our kinetic models of channel bursting and 
reopening pathologies afford a convenient setting to test if the latter hypothesis is sufficient to 
explain mutation-specific pharmacology by these drugs. By assuming that drugs bind to specific 
channel states with the same affinity regardless of channel genotype, we developed models of 
Lidocaine and Ranolazine binding that attribute the majority of our experimental findings to 
mutation-induced differences in channel kinetics.  
Models of Lidocaine and Ranolazine inhibition were constructed with accommodations for 
both the Modulated Receptor Hypothesis (state-dependent binding affinity)70, 71, 103, 104 and the 
Guarded Receptor Hypothesis (state-dependent binding site access)78 (Figure 2.2). Drugs are 
allowed to bind to any channel state (Figure 2.2a), but the ‘on’ rate of binding is limited by 
diffusion through differential access routes70. The binding site, which resides in the central cavity 
of the channel68, may be accessed through the aqueous pore when channels are open (states O and 
BO). All non-conducting channel states must be accessed by a lipophilic diffusion route, which 
selectively permits the passage of small, neutral drug species but not charged species75. Channels 
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are then permitted to transition between drug-bound states with considerations for microscopic 
reversibility favoring the population of states which bind tightest to the drug (Figure 2.2b). We 
constrained the models using whole cell and single channel data sets including block of peak and 
late INa, the kinetics of current inhibition, shifts in the voltage-dependence of channel availability, 
voltage-independent resting state block, and changes in F1473C single channel mean open time. 
We validated these models by comparing the frequency of F1473C reopening in experimental and 
simulated trials. 
Figure 2.5 illustrates the concordance between the model of Lidocaine activity and the 
experimental data, and the rate and state-dependent binding constants are presented in Table 2.3 
(“Original” Model). The simulated F1473C and ∆KPQ currents depicted in Figure 2.5a are 
inhibited by Lidocaine, with preference for inhibition of INaL (insets). The degree of selectivity for 
INaL is greater in the F1473C simulations compared to ∆KPQ, as in our experiments (Chapter 1) 
(Figure 2.45). This model was also constrained by and captures a dramatic hyperpolarizing shift 
in steady-state inactivation that is greater in the ∆KPQ variant than in F1473C (Figure 2.5c). We 
used the voltage-independent reduction in current at -130mV in our steady-state inactivation 
protocol as a measure of resting state block. The Lidocaine model contains sufficient closed-state 
affinity to capture block of F1473C at this voltage, however the model lacks the mutation-specific 
resting state block of ∆KPQ. In addition to steady-state properties of channel inhibition, we 
included as a constraint the kinetics of channel block during a single depolarizing pulse from -
120mV to -30mV (Figure 2.5d). This experimental protocol revealed important differences in the 
kinetics of block in the two mutations, and the mutation-specific kinetics are also present in the 
model. Inhibition of F1473C by Lidocaine develops slowly over time, but inhibition of ∆KPQ 
currents reach a plateau within approximately 20ms. Lastly, this model produces a negligible effect 
55	
	
on single channel mean open time (Figure 2.5f) and produces a mean reduction in the frequency 
of channel reopening (Figure 2.5g) that is similar to our experimental findings, despite not being 
used as a constraint in the optimization of model rates. 
Simulations of Ranolazine activity in F1473C and ∆KPQ are presented in Figure 2.6. While 
the rate and binding constants for Ranolazine (Table 2.4) are quite different than for Lidocaine, 
this model’s strengths and limitations are quite similar to the Lidocaine model. Using the same 
experimental protocols as those used to constrain the Lidocaine model, plus an added constraint 
for an observed 27% reduction in mean open time, the differences in mutant channel gating alone 
are sufficient to account for the magnitude of peak and late INa block (Figure 2.6b), the small but 
significant shift in channel availability (Figure 2.6c), the similar kinetics but differential magnitude 
of F1473C and ∆KPQ inhibition (Figure 2.6d), and a reduction in single channel mean open 
duration (Figure 2.6e). Importantly, this model also predicts a reduction in the frequency of 
F1473C reopening that was similar to our experimental observations (Figure 2.6f), and less 




Figure 2.5. Model of Mutation-Specific INaL Inhibition by Lidocaine. A) Simulated ionic currents at 
high and low (inset) gain of F1473C and ∆KPQ before and after exposure to 200µM Lidocaine using 100ms 
depolarizing pulses to -30mV from a holding potential of -120mV at 1Hz. B) Experimental and Simulated 
effect of 200µM Lidocaine on peak and late INa in F1473C and ∆KPQ. C) Steady-state channel availability 
before and after application of 200µM Lidocaine. Lidocaine causes a hyperpolarizing shift in voltage-
dependent inactivation. Voltage-independent resting state block is taken as the fraction of current inhibited 
at -130mV. D) Kinetics of current inhibition during a single depolarizing step in a train of steps from -
120mV to -30mV. Lidocaine inhibits F1473C and ∆KPQ with different kinetics. E) Histograms of 
simulated late openings after the first 10ms of a sweep before and after application of Lidocaine. To 
replicate our experimental protocols, histograms were compiled from 10 different simulated trials, each 
with 2,000 depolarizing pulses. Mean open time is measured as the time constant of a single exponential 
fit to the data. Lidocaine does not have a significant effect on mean open duration. F) Lidocaine-induced 





Figure 2.6. Model of Mutation-Specific INaL Inhibition by Ranolazine. A) Simulated ionic currents at 
high and low (inset) gain of F1473C and ∆KPQ before and after exposure to 100µM Ranolazine using 
100ms depolarizing pulses to -30mV from a holding potential of -120mV at 1Hz. B) Experimental and 
Simulated effect of 100µM Ranolazine on peak and late INa in F1473C and ∆KPQ. C) Steady-state 
channel availability before and after application of 100µM Ranolazine. Ranolazine causes a 
hyperpolarizing shift in voltage-dependent inactivation. Voltage-independent resting state block is taken 
as the fraction of current inhibited at -130mV. D) Kinetics of current inhibition during a single 
depolarizing step in a train of steps from -120mV to -30mV. Ranolazine inhibits F1473C and ∆KPQ with 
different kinetics. E) Histograms of simulated late openings after the first 10ms of a sweep before and 
after application of Ranolazine. To replicate our experimental protocols, histograms were compiled from 
10 different simulated trials, each with 2,000 depolarizing pulses. Mean open time is measured as the 
time constant of a single exponential fit to the data. Ranolazine significantly shortens mean open duration. 
F) Ranolazine-induced reduction in the frequency of channel opening measured from the same set of 




Table 2.3. Combinatorial Analysis of Lidocaine-Channel Affinity. 
   Parameter Original KdC KdIx KdIS2 KdO kon-lipo 
F1473C 
KdC (µM) 2282.1 3134.6 2141.3 2100.0 2264.1 1896.0 
KdIx (µM) 46.4 55.8 104.3 46.7 46.9 46.3 
KdIS2 (µM) 6.8 13.5 15.3 9.3 6.3 6.9 
KdO (µM) 225.3 162.1 228.3 236.4 439.3 234.2 
kdiff-lipo 0.056 0.052 0.092 0.060 0.064 0.064 
kdiff-hydro 0.15 0.19 0.12 0.14 0.14 0.17 
∆KPQ 
KdC (µM) - 738.5 - - - - 
KdIx (µM) - - 27.2 - - - 
KdIS2 (µM) - - - 5.7 - - 
KdO (µM) - - - - 226.4 - 
kdiff-lipo (µM-1 s-1) - - - -   0.45 
kdiff-hydro (µM-1 s-1) - - - - - - 
  KF1473C/K∆KPQ - 4.2 3.8 1.6 1.9 0.1 
  Global Error  218.3  130.2 140.3  188.8  216.5  190.8 
 
 
Table 2.4. Combinatorial Analysis of Ranolazine-Channel Affinity  
   Parameter Original KdC KdIx KdIS2 KdO kon-lipo 
F1473C 
KdC (µM) 537.0 712.8 517.4 534.0 545.9 549.7 
KdIx (µM) 208.3 194.9 204.0 199.0 214.3 209.3 
KdIS2 (µM) 13.5 14.8 16.5 25.9 13.5 13.4 
KdO (µM) 66.9 64.8 63.3 67.5 74.7 69.5 
kdiff-lipo (µM-1 s-1) 0.022 0.020 0.020 0.019 0.020 0.092 
kdiff-hydro (µM-1 s-1) 6.90 6.90 7.00 7.10 7.00 7.02 
∆KPQ 
KdC (µM) - 364.1 - - -   
KdIx (µM) - - 164.2 - -   
KdIS2 (µM) - - - 12.3 -   
KdO (µM) - - - - 64.7   
kdiff-lipo (µM-1 s-1) - - - -   0.093 
kdiff-hydro (µM-1 s-1) - - - - -   
  KF1473C/K∆KPQ - 2.0 1.2 2.1 1.2 0.98 
  Global Error  420.3  392.9  398.5 385.7  413.2  401.1 
 
Prediction of Mutation-Induced Modifications to Binding Affinity 
The models of Lidocaine and Ranolazine presented above attribute the majority of 
mutation-specific pharmacology to differences in channel gating that alter the distribution of high-
affinity channel states. However, there are some aspects of the pharmacology that are not 
completely recapitulated by these models, particularly the simulation of voltage-independent 
resting state block (Figures 2.5c and 2.6c). It is possible that these discrepancies between the 
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experimental and computational results are due to a limitation in the model topology, or 
alternatively that LQT3 mutations do have an indirect effect on the Kd of drug binding to certain 
states. We therefore employed a combinatorial approach to examine the incremental improvement 
to the model fit by allowing individual binding constants to vary in a mutation-dependent manner. 
Tables 2.3 and 2.4 present the parameters and global error derived after re-optimization of 
all rates while allowing only one to express mutation-dependence. Not surprisingly, this method 
results in an improvement in the error function because the approach requires the inclusion of an 
additional degree of freedom. However, the variability in error function and in the divergence of 
parameters from the original model suggests that some states are more sensitive to mutation-
dependent binding than others.  
The original models for both Lidocaine and Ranolazine were unable to distinguish between 
a difference in resting state block at -130mV. In both cases, allowing KdC to vary between the 
mutations produced a closed-state affinity that was stronger for ∆KPQ channels than for F1473C 
and enabled mutation-specific resting state block (Figures 2.7c and 2.8c) without dramatic changes 
in peak and late block (Figures 2.7b and 2.8b), steady-state inactivation shifts (Figures 2.7c and 
2.8c), or changes in channel mean open time (Figures 2.7e and 2.8e). No other parameters were 
capable of correcting this property when allowed to vary in a mutation-dependent manner. 
Modification of KdC also improved the global error of the minimized objective function more 
effectively than other modifications, suggesting that these models of drug inhibition are 
particularly sensitive to changes in resting state block. It is therefore unlikely that the improved fit 





Figure 2.7. Mutation-specific Closed State Binding by Lidocaine. A) Simulated ionic currents at high 
and low (inset) gain of F1473C and ∆KPQ before and after exposure to 200µM Lidocaine using 100ms 
depolarizing pulse to -30mV from a holding potential of -120mV at 1Hz. B) Experimental and Simulated 
effect of 200µM Lidocaine on peak and late INa in F1473C and ∆KPQ. C) Steady-state channel availability 
before and after application of 200µM Lidocaine. Lidocaine causes a hyperpolarizing shift in voltage-
dependent inactivation. Voltage-independent resting state block is taken as the fraction of current inhibited 
at -130mV, and is improved in this model compared to a model without mutation-varying KdC. D) Kinetics 
of current inhibition during a single depolarizing step in a train of steps from -120mV to -30mV. Lidocaine 
inhibits F1473C and ∆KPQ with different kinetics. E) Histograms of simulated late openings after the first 
10ms of a sweep before and after application of Lidocaine. To replicate our experimental protocols, 
histograms were compiled from 10 different simulated trials, each with 2,000 depolarizing pulses. Mean 
open time is measured as the time constant of a single exponential fit to the data. Lidocaine does not have 
a significant effect on mean open duration. F) Lidocaine-induced reduction in the frequency of channel 




Figure 2.8. Mutation-specific Closed State Binding by Ranolazine. A) Simulated ionic currents at high 
and low (inset) gain of F1473C and ∆KPQ before and after exposure to 100µM Ranolazine using 100ms 
depolarizing pulses to -30mV from a holding potential of -120mV at 1Hz. B) Experimental and Simulated 
effect of 100µM Ranolazine on peak and late INa in F1473C and ∆KPQ. C) Steady-state channel 
availability before and after application of 100µM Ranolazine. Ranolazine causes a hyperpolarizing shift 
in voltage-dependent inactivation. Voltage-independent resting state block is taken as the fraction of 
current inhibited at -130mV, and is improved in this model compared to a model without mutation-
varying KdC. D) Kinetics of current inhibition during a single depolarizing step in a train of steps from -
120mV to -30mV. Ranolazine inhibits F1473C and ∆KPQ with different kinetics. E) Histograms of 
simulated late openings after the first 10ms of a sweep before and after application of Ranolazine. To 
replicate our experimental protocols, histograms were compiled from 10 different simulated trials, each 
with 2,000 depolarizing pulses. Mean open time is measured as the time constant of a single exponential 
fit to the data. Ranolazine significantly shortens mean open duration. F) Ranolazine-induced reduction in 





Figure 2.9. Action potential clamp simulations of current inhibition. A) The WT epicardial ventricular 
action potential of the O’Hara Rudy model after pacing to steady-state at 1Hz stimulation frequency. B) 
Inhibition of peak and late (inset) INa from F1473C channels stimulated by the action potential waveform. 
F1473C (black) currents have a robust INaL compared to WT (gray). 20uM Lidocaine (blue) and 10uM 
Ranolazine (red) preferentially inhibit INaL. C) Inhibition of peak and late (inset) INa from ∆KPQ channels 
stimulated by the action potential waveform. ∆KPQ (black) currents have a robust INaL compared to WT 
(gray). 20uM Lidocaine (blue) and 10uM Ranolazine (red) inhibit INaL with similar selectivity. D) The INaL 
selectivity of Lidocaine and Ranolazine block of F1473C and ∆KPQ. Inhibition of INaL occurs in a 
mutation- and drug-dependent manner. 
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Mutation-specific Inhibition of INaL in Ventricular Action Potentials 
One benefit of computational modeling is the ability to extrapolate fundamental models of 
pathophysiology and disease into a physiologically relevant setting. We applied a WT ventricular 
epicardium action potential waveform (Figure 2.9a) in voltage clamp simulations to examine the 
effects of INaL inhibition in this setting. After 100 beats at cycle length 1s, we analyzed block of 
INa and INaL at the APD50 of homozygous F1473C (Figure 2.9b) and ∆KPQ (Figure 2.9c) cells. 
Both 20µM Lidocaine and 10µM Ranolazine resulted in robust inhibition of peak INa and INaL for 
both mutations, but the preference for inhibition of INaL varied in a mutation- and drug-dependent 
manner. We quantitatively defined INaL selectivity as the ratio of INaL inhibition to peak INa 
inhibition (Figure 2.9d). Peak block of F1473C was larger by Ranolazine, but INaL block was 
smaller, resulting in INaL selectivity that was smaller for Ranolazine than for Lidocaine. 
Conversely, Ranolazine blocks peak and INaL less than Lidocaine in ∆KPQ at these concentrations. 
This resulted in selectivity that was similar for Ranolazine and Lidocaine but pointed to Ranolazine 
as the slightly more effective inhibitor of INaL. These results therefore suggest that the 
pathophysiology of INaL in patients with LQT3 may contribute to heterogeneous responses to local 
anesthetic therapy based on the state-dependent properties of channel inhibition. 
If inactivated channel block by Lidocaine is more effective for selective INaL inhibition in 
F1473C, and open channel block by Ranolazine is more effective in ∆KPQ, then novel theoretical 
inhibitors which emphasize these properties are likely to enhance selectivity. To test this 
hypothesis, we employed a sensitivity analysis which estimates the relative role of each binding 
parameter in conferring preferential inhibition of INaL. For each of the six parameters we performed 
20 action potential clamp simulations in which the parameter in question was perturbed from the 
best fit of the Lidocaine or Ranolazine models by a random percentage between 50% and 150%. 
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Important differences in the sensitivity of mutant channel inhibition emerged from this analysis. 
Figure 2.10a presents representative simulated control ∆KPQ currents, currents inhibited by the 
optimized Ranolazine model, and currents after modulation of the open state Kd. Neither increasing 
nor decreasing KdO had an effect on inhibition of peak INa, but INaL block was inversely correlated 
with changes in KdO. Stronger open state binding resulted in more INaL block and greater INaL 
selectivity. To investigate the quantitative sensitivity of changes in KdO relative to other binding 
parameters, we plotted the normalized INaL selectivity against the parameter deviation (Figure 
2.10b). These relationships were fit well by linear models within the range of parameter space 
tested here (R2>0.95 in all cases). The slopes of these relationships varied widely, with KdO and 
KdIS2 having large but opposing effects on INaL selectivity. Surprisingly, the model was the least 
sensitive to changes in the diffusion rate constants. 
We performed this sensitivity analysis on all drug-mutation combinations, and report the 
slope of the parameter-selectivity relationship (Figure 2.10c-f). In all cases, KdC and KdIS2 have 
large positive slopes, and relieving affinity to these sites improves INaL selectivity. The sensitivity 
profiles of ∆KPQ inhibition by Lidocaine and Ranolazine are similar, and point to a beneficial 
effect of strengthening open state binding while limiting inactivated state binding. In contrast, 
F1473C block sensitivity is dependent on the baseline parameters, with an increase in KdI 






Figure 2.10. Sensitivity analysis of state-dependent drug binding. A) Representative simulated 
currents from ∆KPQ during action potential clamp simulations. Currents before and after application of 
100µM Ranolazine are compared to currents exposed to derivatives of Ranolazine with modified open 
channel affinity. B) Sensitivity of INaL selectivity of DKPQ inhibition by Ranolazine to modifications in 
each of the six model parameters. Data is well described by a linear relationship (R2>0.95). The model is 
most sensitive to changes in open channel and slow-inactivated channel affinity with opposing effects. C 
to E) Extracted slopes of sensitivity analysis of F1473C and DKPQ inhibition by 200µM Lidocaine and 
100µM Ranolazine. Negative slopes (red) indicate a decrease in selectivity with increased parameter 




State-dependent Access and Binding of Local Anesthetics 
Since the proposal of the Modulated Receptor Hypothesis by Hille in 197770, state-
dependent drug-channel affinity has been used to explain shifts in the voltage-dependence of 
channel availability, use-dependent block, and preferential inhibition of INaL. On the basis of whole 
cell and single channel observations, Lidocaine has long been understood to interact preferentially 
with inactivated channels and to access the local anesthetic binding site through a lipophilic 
pathway75. Ranolazine on the other hand, has been modeled to interact preferentially with open 
channels49. Our simulations presented here provide a quantitative description of the differential 
activity of Lidocaine and Ranolazine that confirms these earlier findings. Lidocaine interacts 
selectively with inactivated channels (KdILidocaine = 46.4µM; KdIRanolazine = 208.3µM), while 
Ranolazine binds more tightly to open channels (KdOLidocaine = 225.3µM; KdORanolazine = 66.9µM). 
These differences in state-dependent binding are reflected in the nature of their interaction with 
F1760, the local anesthetic binding site. Lidocaine has been shown to bind via a specific cation-π 
interaction with this residue that was absent in Ranolazine binding77. It is therefore likely that these 
molecules reside in the central pore of the channel in a manner which alters the geometry, and 
state-dependence, of interaction at this site. 
Interestingly, though, these binding affinities themselves have little bearing on the effect 
of drugs on channel mean open time. The Kds presented here are an estimate of equilibrium drug 
binding, but Na+ channel gating is highly dynamic and rarely near equilibrium. The relative 
diffusion rate constants therefore play a very important role in the kinetics of channel inhibition 
and the effect on channel mean open time. Here we present evidence that the on-rate of Ranolazine 
binding through a lipophilic access pathway (kdiff-lipophilic) is slower than for Lidocaine, while 
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the on-rate for hydrophilic binding (kdiff-hydrophilic) to the open state is faster. Ranolazine is larger 
than Lidocaine with more hydrogen bond acceptors (6 vs 2), a wider polar surface area (75.5 Å2 
vs 33.5 Å2) but similar pKa and partition coefficient94. It is therefore likely that its size and polarity 
impinge its ability to penetrate the small, intramembrane lipophilic pathway to the binding site 
predicted by Hille70 and identified in crystal structures of the bacterial channel NavAB18, 19. 
 
Mechanisms of Mutation-specific Inhibition of INaL 
Peak INa is critically important to rapid cardiac conduction, and reductions in the early 
transient by drugs11 or mutations5, 105 can itself be proarrhythmic. Local anesthetics have long been 
used in the treatment of LQT3 because of their ability to preferentially inhibit INaL with a smaller 
effect on peak INa. The emerging interest in precision medicine requires a more detailed 
understanding of phenotypic differences in the etiology of INaL that impact the efficacy and safety 
of these drugs. Chapter 1 presented a series of experiments documenting important 
pharmacological differences between Lidocaine and Ranolazine inhibition of F1473C and ∆KPQ. 
We asked if the differences in mutant channel gating were sufficient to account for unique 
responses to blockade by constructing models of INaL inhibition under the assumption that mutant 
channels have equivalent state-dependent binding rates and affinities. Models of both drugs 
captured several of the mutation-specific signatures we identified experimentally, and the 
underlying distribution of channel states therefore has a large impact on the action of state-
dependent channel blockers. 
Both the rapid recovery from inactivation and late reopenings of the F1473C mutation are 
signatures of impaired channel inactivation. It is therefore not surprising that Lidocaine, a drug 
shown here and previously to associate preferentially with inactivated channels74, 89, 90, 102, 106, is 
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more effective at stabilizing these faulty processes. Because late reopenings have the same 
duration as the channel openings that give rise to the peak Na+ transient, open channel block by 
Ranolazine is unable to differentiate peak INa from INaL and is less effective at correcting the 
underlying gating dysfunction. On the other hand, the openings during channel bursting in ∆KPQ 
have a prolonged duration compared to early openings, allowing for more time over which 
Ranolazine54 may bind to its high affinity state and exert a preferential inhibition of the 
pathological current. Lidocaine, with its relatively slow and low affinity open channel binding, 
does not have this effect.  
The cases of Lidocaine and Ranolazine presented here serve as foundation for a general 
examination of local anesthetics with different state-dependent properties. A sensitivity analysis 
allowed us to generate a virtual library of local anesthetic derivatives to ask if specific qualities of 
these drugs can be accentuated to improve INaL selectivity. Our analysis points to slow inactivated 
state and closed state binding as generally detrimental to selective INaL block in all drug-channel 
combinations. Only enhancement of open state binding provided consistent improvement in 
selectivity, with a greater impact on ∆KPQ where a larger fraction of INaL is derived from bursting. 
Interestingly, manipulation of inactivated state binding responded in a mutation- and drug-
dependent manner. This is because, in our model, inactivated state binding not only stabilizes fast 
inactivation but also induces a hyperpolarizing shift in channel availability which results in adverse 
effects on peak INa. ∆KPQ, with a V1/2 of inactivation near the resting membrane potential, 
responds dramatically to hyperpolarizing shifts in availability. F1473C, on the other hand, causes 
a depolarizing shift that allows for more leeway. The highest degree of F1473C INaL selectivity in 
this mutation would therefore be a drug which differentiates IF and ICx binding, a property not 
currently attainable given the simplifying assumptions of our model. 
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Despite the fact that our models capture most of the important aspects of mutation specific 
pharmacology through differences in channel gating, some remaining discordance between the 
model and data suggest that this simplifying assumption may not be wholly accurate. In fact, a 
combinatorial approach to examining the role of mutation-specific Kds revealed a potentially 
important modification to closed-state binding affinity by some LQT3 mutations. The suggestion 
that LQT3 mutations alter the affinity of closed channels is novel, and is interesting given the 
location of these mutations in the DIII/DIV linker near the inactivation gate, a region not 
previously thought to interact with the pore domains in the closed state. Alternatively, it is possible 
that the 0.1Hz stimulation frequency in these experiments is insufficiently long to allow the system 
to reach steady-state, resulting in apparent differences in resting state tonic block that are actually 
due to mutation-specific recovery from inactivation. These findings highlight the need for a more 
detailed structural understanding of the local anesthetic binding site, its allosteric interactions with 
the inactivation machinery, and the geometrical arrangement of channel inhibitors within the pore 
in different channel states. 
 
In silico Screening of Patient-Specific Outcomes 
Our growing understanding of the genetic basis for cardiac arrhythmia and the patient-
specific response to pharmacological intervention brings with it the need for novel experimental 
models of disease. Unfortunately, reliable experimental models of INaL that account for human 
physiology and the genetic heterogeneity of LQT3 patients are hard to come by; primary human 
tissue is rare, animal models are low throughput, and induced pluripotent stem cell derived 
cardiomyocytes remain under-developed for detailed systems analysis. Computational modeling 
has emerged as a useful tool in investigating ion channel function and the systems pharmacology 
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the heart. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) Initiative, for example, seeks 
to establish new guidelines for the prediction of drug-induced arrhythmia through a combination 
of in vitro and in silico approaches to supplement or replace clinical thorough QT trials107. 
Here we present a framework for the patient-specific screening of local anesthetic drugs in 
a pair of divergent channel phenotypes. While our models of Lidocaine and Ranolazine are based 
on specific experimental data, their unique chemical properties and pharmacological profiles allow 
for a general examination of local anesthetics with different properties. Our modeling predicts 
important differences in the response of channels with different gating pathologies based on the 
distinctive state-dependent binding properties of the drug. With an ever expanding registry of 
functionally characterized channel phenotypes, this sort of in silico prediction will help to guide 
development of novel inhibitors and the design of patient-specific treatment regimens in patients 
with inherited or acquired QT prolongation. 
 
Limitations 
There are inherent limitations in the use of computational models because of the 
simplifying assumptions required for model identifiability97. These models were constructed using 
one concentration of drug in experiments performed at room temperature and in a model system 
(HEK 293 cells) designed to isolate channel function. Simulations using action potential-clamp 
conditions also do not account for secondary actions of these drugs on other ion channels, such as 
hERG (which conducts IKr), or feedback mechanisms such as Ca2+ handling and Ca2+ dependent 
effects on INa. Future incorporation of these pharmacological models into whole myocyte models 
will allow for the prediction of drug effects on even more clinically relevant physiological 














Chapter 3: Utilization of unnatural amino acids to study the chemistry of  





State-dependent channel inhibition can help to explain many of the important properties of 
local anesthetic pharmacology, including preferential inhibition of late Na+ current (INaL). We 
previously established that Lidocaine and Ranolazine exhibit distinct mutation-specific effects on 
two Long QT 3 associated mutations, F1473C and ΔKPQ (Chapter 1). Simulations of mutant 
channel gating and state-dependent drug binding revealed that differences in channel kinetics are 
sufficient to explain the majority of these effects (Chapter 2). However, the ability of our model 
to recapitulate resting state pharmacological properties of local anesthetics suggest that there are 
important structural effects of F1473 and ΔKPQ mutations at the drug binding site that alter 
binding affinity in a way not captured by our models. The dynamic nature of voltage-gated Na+ 
channel gating and the relative lack of structural information about the channel make any chemical 
understanding of selective INaL inhibition difficult. Recently, unnatural amino acids were employed 
to make direct measurements of a specific cation-𝛑 interaction important in use-dependent block 
of cardiac Na+ channels. This chapter details the use of unnatural amino acids to investigate the 
role of this interaction in state-dependent drug binding and selective inhibition of INaL, lending a 
structural perspective to the quantitative predictions of our kinetic models. However, we present 
here evidence that the unnatural amino acids themselves disrupt inactivation gating, limiting the 
ability to distinguish their effects on pharmacology as a modulation of drug-channel affinity or as 






During the plateau phase of the cardiac ventricular action potential INa has nearly 
completely inactivated and contributes little to the balance of ionic fluxes governing the membrane 
potential. However, there exist several disease states and mutations for which a failure to inactivate 
results in a sustained inward late current (INaL) that results in prolongation of the action potential, 
prolongation of the QT interval, and increased risk of ventricular arrhythmia and sudden cardiac 
death5, 10. INaL has therefore become an important therapeutic target, and efforts are underway to 
develop novel, potent, and selective inhibitors4, 58, 95. We previously reported that two such INaL 
inhibitors, Lidocaine and Ranolazine, exhibit unique state-dependent binding properties. These 
properties, when applied to two mutations with unique molecular etiologies of INaL, result in strong 
mutation-specific differences in block of peak INa and in selectivity for INaL. Computational 
analysis revealed that most of these mutation-specific effects can be attributed to differences in 
channel gating that alter the kinetics and distribution of high-affinity channel states. However, 
some lingering discordance between our models and experimental data raises the possibility that 
mutations alter the thermodynamics of the interaction between the drug and the channel. Moreover, 
our models predict state-dependent drug-channel interactions that are important in preferential 
inhibition of INaL, so a refined understanding of the precise chemical interactions governing these 
properties would guide the rational development of more selective molecules. 
The local anesthetic binding site resides in the central conducting pathway just below the 
selectivity filter9. Mutational analysis has revealed several residues important in tonic and use-
dependent block (UDB) of INa, however one mutation, F1760A, results in a particularly severe 
abolishment of current block67. Mutation of F1760, located on S6 of domain IV, impairs UDB and 
INaL inhibition by many common channel blockers including Lidocaine68, Mexiletine69, and 
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Ranolazine47. These findings raised an interesting question: how does an aromatic residue 
contribute significantly to the binding of organic cations? To answer this question a more precise 
chemical tool is needed. 
Unnatural amino acid (UAA) technology allows one to expand the genetic code with 
selective incorporation of a UAA at any site of interest108. After enzymatically ligating a synthetic 
dinucleotide-fused UAA to a tRNA with anticodon CUA, this ‘charged’ tRNA and ion channel 
Figure 3.1. Unnatural Amino Acid Incorporation into Functional Nav1.5. A) Nonsense suppression 
workflow. Synthetic amino acids are chemically conjugated to a dinucleotide, which is ligated to tRNA. 
UAA-tRNA and mRNA containing the TAG ‘stop’ codon are co-injected into Xenopus oocytes for two-
electrode voltage clamp experiments. B) UAAs are incorporated at the LA binding site, F1760, which resides 
in the central cavity on S6 of D4. C) Fluorophenylalanine derivatives with monotonically reduced electron 
density of the π-electrons in the aromatic ring. D) Chemical structure (top), energy minimized 3-D structure 
(middle), and electrostatic potential map (bottom) of Mexiletine. The cationic head group is clearly visible 
in blue.  
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mRNA are co-injected into Xenopus oocytes for two electrode voltage clamp recording. The 
mRNA is engineered with a UAG ‘Stop’ codon at the position of interest, so that any emergent 
peptide that fails to incorporate a UAA is truncated and non-functional. Successful incorporation 
results in a full-length peptide in a process known as Nonsense Suppression109, 110. This procedure 
is detailed in Figure 3.1a. 
Ahern and Horn first used Nonsense Suppression in voltage-gated Na+-channels in 2008 
to incorporate unnatural derivatives of phenylalanine at site F1579 of Nav1.4, a muscle isoform of 
the voltage-gated Na+-channel76. This residue is highly conserved among Navs and is homologous 
to F1760 in Nav1.5 (Figure 3.1b). The UAAs substituted one, two, or three fluorine atoms in place 
of the hydrogen atoms of the aromatic ring (Figure 3.1c). With the addition of each new 
electronegative fluorine the π-electrons are drawn away from the face of the aromatic ring, 
decreasing the strength of the partial negative charge without altering the residue’s size, shape, 
polarizability, or hydrophobicity. Mexiletine, a closely related derivative of Lidocaine, contains a 
cationic head group that is attracted to these π-electrons (Figure 3.1d). As the number of fluorine 
substituents on F1760 is increased there is a monotonic reduction in the potency of UDB by 
Mexiletine, but not in the potency of tonic block, reflecting important conformational changes that 
occur during channel opening and/or inactivating that unmask the binding site76. The authors 
propose that drug binding via the cation-π interaction stabilizes these states, providing a structural 
basis for the state-dependent binding predictions of the Modulated Receptor Hypothesis70. We 
reasoned that the allosteric stabilization of inactivation that contributes to UDB likely also 
contributes to preferential inhibition of INaL, and therefore that the cation-π is an important 
chemical determinant of INaL block, as well. 
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In this chapter, we test the hypothesis that the elevated block of INaL compared to peak INa 
is associated with a concomitant increase in the strength of the cation-π interaction during a single 
depolarizing pulse. This finding would suggest that the conformational states populated during 
prolonged membrane depolarization promote favorable conditions for the formation of this 
interaction, providing an actionable chemical target for the future development of selective INaL 
inhibitors. In concert with the kinetic studies of channel gating and inhibition in Chapter 2, these 
findings would lend a chemical perspective to the state-dependence of drug binding, and enhance 
our understanding of the structural relationship between the inactivation gating machinery and the 
local anesthetic binding site. 
 
Methods 
Molecular Biology and Unnatural Amino Acids 
In vivo incorporation of UAAs was performed by the nonsense suppression method as 
previously reported76, 77. Mutations in SCN5A, the gene encoding Nav1.5, were engineered into the 
WT gene in pcDNA3.1 using overlapping primers and the QuikChange site-directed mutagenesis 
kit (Qiagen). In addition to the F1473S and F1760TAG mutations, we also introduced the C373Y 
mutation which confers TTX-sensitivity111. mRNA was transcribed using the mMessage 
mMachine T7 RNA Transcription Kit (Ambion). cDNA for Tetrahymena thermophile tRNA 
containing the CUA anticodon was provided in pcDNA3.1 by the Dr. Chris Ahern (University of 
Illinois). tRNA was transcribed using the mMessage mMachine T7 RNA Transcription Kit, ligated 
to aminoacyl dinucleotide using T4 RNA Ligase (Ambion) and purified with the RNAeasy Mini 
Kit (Qiagen). Aminoacyl dinucleotides were generously provided by the Ahern Lab as a precipitate 
and dissolved prior to use to 3mM in H2O. 
77	
	
To enhance the yield of aminoacyl dinucleotide synthesis the amino acid is protected with 
nitroveratryl oxycarbonyl. Immediately prior to injection, aminoacyl-tRNAs were deprotected by 
UV irradiation for 6 minutes. 25ng aminoacyl-tRNA, 25ng F1473S/F1760TAG mRNA, and 5ng 
mRNA encoding the hb1 subunit were mixed and injected into Xenopus oocytes. Na+-currents 
were recorded 18-24 hours after injection. Negative control experiments performed without co-
injection of aminoacyl-tRNA showed no TTX-sensitive currents over this time range.  
TTX was purchased from Abcam and used at a final concentration of 50nM. Mexiletine 
was purchased from Sigma and 100mM stocks were made in H2O. 
 
Two Electrode Voltage Clamp Recording 
Voltage-gated Na+-currents were recorded using two electrode voltage clamp at room 
temperature (~22°C). Currents were amplified using a Axopatch 200A (Axon Instruments) and 
digitized with a Digidata 144A (Warner Instrument Corp). The extracellular bath solution 
contained (mM): 116 NaCl, 2 KCl, 1 MgCl2, 0.5 CaCl2, 5 HEPES, pH7.4 adjusted with CsOH. 
Glass microelectrodes were pulled to a resistance between 0.1 and 1.0 MW and backfilled with 3M 
KCl prior to use. Cell membranes were held at -100mV. Currents were elicited by depolarizations 
to -20mV for 400ms at 0.2Hz. Recordings were analyzed in Clampfit 8.0 (Molecular Devices 
LLC). TTX-subtraction was performed on control and Mexiletine traces. 
 
Statistics 
Data are presented at mean ± standard error. Statistical significance was determined by a 
Student’s T-test with significance level p<0.05. For comparisons across multiple groups statistical 
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significance was determined with a one-way ANOVA with significance level p<0.05, and 






Expression of LQT3 Mutant Nav1.5 with Unnatural Amino Acids 
In order to test the role of the cation-π interaction in preferential inhibition of INaL, we 
incorporated a spectrum of UAAs into mutant F1473S Nav1.5 at site F1760 in Xenopus oocytes. 
We chose the naturally occurring F1473S mutation as a model because its robust INaL provided 
ample resolution to detect small changes in channel block in the presence of UAAs112. In the 
absence of charged aminoacyl-tRNA, F1473S/F1760TAG expressing cells did not display any 
Na+-current in the time frame tested. Co-injection of F1473S/F1760TAG with Phe-, monofluoro- 
(F1), difluoro- (F2), or trifluoro-tRNA (F3) resulted in nonsense suppression rescued currents 
(Figure 2a). The incorporation of fluoride atoms reduced the efficiency of peak INa rescue 
(Figure2b), but the rescued F1473S currents provided ample INaL that is resolvable even at low 
gain.  
We examined INaL in these cells with depolarizing pulses from -100mV to -20mV for 
400ms at 0.2Hz. We used long pulse durations and a slow frequency to ensure that any drug block 
observed during prolonged times was the result of conformational changes arising during that 
pulse, with no contribution from the accumulation of channels in drug-bound states that arises 
during faster pacing rates. There are significant differences in the magnitude of INaL relative to 
peak INa across the spectrum of UAA-incorporating channels (Phe: 6.89±0.96%, F: 6.06±0.38%, 
F2: 10.74±0.67%, F3: 9.25±1.33%, p<0.01). It is possible that the physiologic concentrations of 
Na+ used in these experiments resulted in poorly controlled voltage clamp, improper measurement 
of large Na+ transients and, consequently, miscalculation of INaL as a fraction of peak INa. We 
therefore repeated experiments with Phe and F2 F1473S/F1760TAG using lower 30mM 
extracellular Na+ (Figure 2d). These conditions resulted in smaller currents, yet the F2-induced 
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increase in INaL (5.03±0.30% vs 10.19±0.98%, p<0.001) was still observed. In addition, the 
improved voltage-control obtained by decreasing extracellular Na+ allowed us to measure the time 
course of fast inactivation. F2 caused a slowing of the time to half-peak (1.55±0.08ms vs 
2.23±0.13ms, p<0.01). These results suggest that even small modifications to F1760 such as 
fluorine substitutions can result in altered fast inactivation kinetics and substantial INaL. 
 
Figure 3.2. Nonsense Suppression of Mutant Nav1.5 with Fluorophenylalanine. A) Representative TTX-
sensitive traces of F1473S/F1760TAG Nav1.5 containing Phe (n=3), fluoro-Phe (n=9), difluoro-Phe (n=9), or 
Tripler-Phe (n=6) at position 1760.Note the substantial INaL that is resolved in these low gain recordings. INaL 
is resolvable even at low gain. B) Average peak INa current in rescued F1473S/F1760TAG is diminished in 
the presence of fluorinated derivatives. C) Current measured at 400ms as a percentage of peak INa varies in 
the presence of fluorphenylalanines. D) Current measured at 400ms as a percentage of peak from experiments 
with low 30mM extracellular Na+ in Phe (n=7) and F2 (n=5) expression oocytes. F2 induces an increase in 




Mexiletine Inhibition of LQT3 Channels with Altered LA Binding Site 
To test inhibition of these channels by local anesthetic-like drugs, we applied 100µM 
Mexiletine to the bath solution and recorded drug-exposed currents in the same cells. Mexiletine 
is a commonly prescribed oral Na+-channel inhibitor and antiarrhythmic similar to Lidocaine. 
Previous studies revealed a strong cation-π interaction that contributes to UDB of WT channels by 
Mexiletine77. We did not analyze inhibition of peak INa in these experiments because of variable 
voltage-control. Mexiletine inhibited INaL in all constructs tested (Figure 3.3a). If a cation-π 
interaction contributes to preferential inhibition of INaL, then block of INaL at 400ms should be 
diminished as the number of fluoro-substituents is increased. We did not observe monotonically 
reduced inhibition of INaL with the addition of each fluorine (Figure 3.3b). Rather, inhibition of 
INaL in F2 F1473S/F1760TAG channels was greater than in the other constructs (p<0.001). 
Inhibition of INaL therefore mirrors the differences in INaL magnitude across these constructs, 
Figure 3.3. Mexiletine Inhibition of F1473S Channels with Modified Binding Site. A) Representative 
F1473S/F1760TAG-Phe- (n=3), F1- (n=8), F2- (n=9), and F3- (n=6) phenylalanine recordings in control (grey) 
and 100µM Mexiletine (black) conditions.. B) Quantification of INaL inhibition by Mexiletine at the end of a 




raising the possibility that the unique and unpredictable changes to channel gating introduced by 
the UAAs contributes to this pharmacological profile, limiting our ability to interpret the results 
as due to changes in the cation-π interaction. 
  
Discussion 
Here for the first time we incorporated UAAs into Nav1.5 in the presence of LQT3-
associated mutations. We sought to correlate depolarization-time-dependent changes in a critical 
cation-π interaction with enhancements in channel inhibition that lead to preferential block of INaL. 
This cation-π interaction is critical in UDB by Mexiletine and Lidocaine77. We reasoned that the 
gating transitions underlying UDB - namely, stabilization of inactivated states and a subsequent 
accumulation of refractory channels - are also likely to underlie inhibition of INaL. If a cation-π 
interaction is important in preferential block of INaL, then with the addition of each sequential 
fluorine atom to the aromatic ring the potency of INaL inhibition will decrease. However, UAA-
induced changes in inactivation gating (t1/2 and INaL) limited our ability to interpret these results as 
a change to the cation-π interaction itself. 
Chapter 2 presented a computational model of channel inhibition with the assumption that 
mutations do not influence the physical chemical interaction of drugs and channels or, in other 
words, that the putative cation-π interaction is not impacted by channel mutations. With this basic 
assumption the mutation-specific pharmacology recapitulated by these models can be attributed to 
differences in channel gating that alter the distribution of high-affinity channel states. The 
modification of INaL by fluoro-Phe substituents, particularly by di-fluoro-Phe, indicates modulation 
of inactivation gating that could translate into altered pharmacological responses, similar to the 
phenotypic and pharmacological differences between the F1473C and ΔKPQ mutations. It is 
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therefore possible that the observed profile of INaL inhibition in fluoro-Phe-containing mutant 
Nav1.5 is due not to modulation of the cation-π interaction, but to kinetic differences between 
experimental conditions that enhance or diminish channel block. While our experiments do not 
rule out a role for the cation-π in preferential inhibition of INaL, they are unable to directly detect 
its role or magnitude.  
It is not surprising that modulation of the chemistry of F1760 destabilizes channel 
inactivation and promotes INaL. Despite the limitations of this study to determine the role of a 
cation-π interaction in inhibition of INaL, important lessons can still be gleaned regarding the broad 
conformational changes associated with inactivation gating and the local anesthetic binding site. 
Our work and the work of others has shown that drug binding to inactivated channels produces a 
stabilizing effect on channel inactivation113. Previous work examined the accessibility for MTS 
reagents to an engineered cysteine at site 1760, and demonstrated that covalent modification of 
F1760 enhanced and stabilized slow inactivation and UDB89, 102, 106, 113. Similarly, fluorometry74, 
92, cysteine accessibility72, 73, and gating charge114, 115 analysis of voltage sensor movement 
indicated that activation of S4 in DIII and, in part, DIV is closely coupled to inactivation gating 
and is stabilized in the presence of Lidocaine. This sort of allosteric modulation of channel 
behavior is likely to be bi-directional: destabilization of the drug binding site should have an effect 
on the closely coupled processes of channel inactivation. In fact, several studies have reported 
changes in steady-state and slow inactivation when F1760 is mutated to other residues113 or 
modified by MTS reagents37. Even our small fluorine substituents at F1760 are sufficient to perturb 
the structure of this site and impair channel inactivation. 
Taken together with the in vitro experiments of Chapter 1 and explanatory models of 
Chapter 2, these findings provide a framework for the development of novel mutation-specific 
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therapeutics. Lidocaine was a more selective inhibitor of INaL than Ranolazine in F1473C channels, 
for which the primary channel pathology was a deficiency in slow inactivation. Lidocaine interacts 
primarily with inactivated channels and exhibited a powerful cation-π interaction for UDB76, 77. 
Conversely Ranolazine77, which is established above and by others as an open-channel blocker, 
did not demonstrate a role for cation-π in UDB. The cation-π therefore appears to be a chemical 
signature of high affinity inactivated state block. This suggests that rational targeting of the cation-






The marriage of experimental and in silico approaches is gaining traction as a valuable tool 
in drug discovery, particularly in dynamic systems such as ion channel function and pharmacology. 
One emergent use of such an approach is in the study of patient heterogeneity and prediction of 
safety and efficacy in patient subpopulations. This thesis presents a proof of concept that 
computational modeling based on detailed experimental characterization of ion channel 
pharmacology can generate novel insights into patient-specific therapy. 
In Chapter 1, we characterized a recently discovered mutation, F1473C, which varied quite 
significantly in its gating properties from the canonical ∆KPQ mutation. In simple terms, ∆KPQ 
causes channel bursts that occur relatively rarely but with very long duration. F1473C, on the other 
hand, results in a gating abnormality that occurs 100-fold more often than channel bursts, but with 
a much shorter duration. While this phenotype has been reported previously in other mutations, 
the F1473C mutation causes a particularly severe case of reopening that enabled its use as a tool 
in the study of pharmacology. The two main drugs used in this study, Lidocaine and Ranolazine, 
impacted reopenings in distinct ways. The distinguishing feature of these two drugs is the 
prominent effect on mean open time by Ranolazine.  
Not surprisingly, the single channel properties of our two mutations and two drugs 
translated into mutation- and drug-specific pharmacology at the whole cell level. Lidocaine proved 
to inhibit F1473C with dramatically higher selectivity than ∆KPQ, and did so with kinetics that 
were reflective of the relative kinetics of INaL. Ranolazine did not distinguish between the kinetics 
of INaL in the same way, and only resulted in elevated block of peak and late ∆KPQ current. These 
experiments clearly laid out the heterogeneity in channel gating and local anesthetic activity, but 
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the causes and implications of such variability are difficult to decipher without a more quantitative 
analysis. 
Chapter 2 focused on the construction of versatile models that provide a mechanistic 
framework for our experimental studies and allow for exploration of local anesthetic 
pharmacology to drive additional hypothesis. The history of in silico pharmacology in LQT3 is 
one of continual refinement and iterative growth. We built on the careful work of others to devise 
a model for WT channel gating based on data from a new experimental protocol that more 
completely defines important transitions. Next, using only small modifications to this model, we 
simulated virtual LQT3 mutant currents with properties similar to F1473C and ∆KPQ. From these 
models it is quite clear how modest changes in channel gating can cause dramatic differences in 
the distribution of channel states – an interesting finding considering the co-localization of these 
two mutations to the same region of the channel. Using our experimental data as a guide, we 
demonstrated that it is this distinction in the distribution of states that causes most of the mutation-
specific effects of Lidocaine and Ranolazine. Such a finding implies that models of state-
dependent local anesthetic binding are generalizable, and predictions about the selectivity for INaL 
in any drug-channel combination can be made if the properties of the mutant channel and drug are 
known independently. Moreover, the ease with which model parameters can be varied establishes 
the setting for high throughput screening of novel virtual therapeutics. 
In Chapter 3, we present an effort to extend observations about the role of state-dependent 
binding affinity in block of INaL, and gain a detailed chemical understanding of drug-channel 
interactions. The dynamics and structural complexity of Nav1.5 gating have made traditional 
ligand binding assays difficult. The application of unnatural amino acid technology to voltage-
gated ion channels has helped to overcome this challenge. We reasoned that a cation-π interaction 
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known to play a role in use-dependent block was likely also responsible for the growth in current 
block during a single pulse that enables preferential block of INaL. Using fluorinated derivatives of 
phenylalanine, we attempted to measure this interaction during Mexiletine inhibition of a very 
sever LQT3 mutation, F1473S. The introduction of variable INaL and inactivation kinetics by these 
residues confounded our ability to interpret changes in drug inhibition. Our experiments do not 
rule out the role of the cation-π in block of INaL.  
In conclusion, this work is an important step in deciphering the complex heterogeneity in 
patients with heritable cardiac arrhythmias. In vitro data will continue to be critical in the 
characterization of individual mutations, but understanding the complex roles that these mutations 
play in pharmacology requires a more analytic quantitative approach. Constructing model 
platforms that acknowledge this heterogeneity is a critical step in developing patient-specific 











Our models of the pathophysiology and pharmacology of INaL have taught us valuable 
lessons about the molecular etiology of mutation-specific responses to local anesthetic inhibition. 
However, models often raise more questions than they answer and serve as a useful tool in the 
development of new experimental hypotheses. This section will address certain strengths and 
limitations of the work presented here, and propose several experiments and simulations to 
advance the field. 
 
Systems Pharmacology of INaL 
The models presented in Chapter 2 treat INa as an isolated current, such as one measured 
experimentally in heterologous expression systems. Even our voltage-clamp simulations using 
action-potential waveforms treat INa explicitly as a model output. In reality, INa is only one of 
several ionic currents from various channels, pumps, and transporters in the ventricular myocyte, 
each with a distinct localization to subcellular compartments8. The ventricular action potential 
waveform is derived from the integration of each of these ionic currents, with constant feedback 
between current and voltage. Several models have been developed to capture the systems biology 
of the ventricular myocyte and use current-clamp configurations to simulate ionic fluxes and 
membrane potential98. The most widely used model of the human ventricular action potential is 
the O’Hara-Rudy model101. Incorporation of our revised Nav1.5 Markov model, LQT3 mutant 
currents, and local anesthetic activity would allow predictions of mutation-specific pharmacology 
on the clinically relevant measures of upstroke velocity and action potential duration. Such a model 
would also facilitate an exploration of the systems biology of different flavors of INaL. For example, 
the resultant increased flux of Na+ is known to alter the properties of the Na+/Ca2+ exchanger, 
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CaMKII signaling, and Ca2+ dynamics, which may serve as the trigger for early 
afterdepolarizations and arrhythmia60, 116, 117. 
We replaced the INa and INaL calculations in the O’Hara-Rudy model with two copies of 
our WT model to allow for the virtual expression of heterozygous mutant INa. Our experiments 
and simulations were performed at room temperature (~24ºC), but the ventricular myocyte model 
is simulated at 37ºC. We therefore adjusted all of the transition rates in our model for temperature 
Figure 4.1. Temperature-dependence of simulated INaL. A) Simulated epicardial ventricular action 
potentials of the O’Hara Rudy model at 1Hz steady-state pacing. Replacement of the Hodgkin-Huxley 
formulation INa in the published model (gray) with the Markov channel model (black) resulted in action 
potentials with similar morphology and APD. B) Calibration of GNa after replacement of INa in the O’Hara-
Rudy model resulted in similar upstroke velocity and peak membrane potential. C) Virtual expression of 
heterozygous F1473C (red) and DKPQ (blue) caused substantial action potential prolongation at 1Hz 
steady-state pacing. DKPQ caused a more dramatic effect than F1473C. D) Simulated INaL during the 
action potentials in (C). Heterozygous DKPQ expression resulted in a larger INaL. E and F) Voltage-clamp 
simulations of F1473C and DKPQ currents using the ventricular action potential waveform at 24oC and 
37oC using Q10=3. INaL in F1473C was reduced by increasing temperature, while INaL in KPQ was not. 
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(Q10=3)49. After calibrating the relative conductance of INa (GNa = 3.4) to match the peak INa from 
the OHR model, we simulated steady-state action potentials using 1Hz current-clamp pacing and 
measured APD90 (Figure 4.1a) and upstroke velocity (Figure 4.1b) that were similar to the original 
model.  
Virtual expression of heterozygous F1473C and ∆KPQ currents resulted in action potential 
prolongation (Figure 4.1c) and INaL (Figure 4.1d). Surprisingly, F1473C prolonged the action 
potential less severely, contrary to the larger INaL that we observed experimentally and reproduced 
in simulated square pulse experiments at room temperature. This suggests that, in our models, 
these two mutations may respond differently to changes in temperature. To test this possibility, we 
returned to action potential voltage-clamp simulations and compared INaL at 24ºC and 37ºC. INaL 
in the F1473C model reduced dramatically with increased temperature (Figure 4.1e), but ∆KPQ 
did not (Figure 4.1f).  
These mutations, while both in the DIII/DIV linker, alter channel gating in unique ways 
and likely cause different structural deformities and allosteric effects on distant channel regions. 
There currently exists no data to suggest that all channel conformational changes respond the same 
to temperature. Our modeling suggests that applying the same temperature-dependence to all rates 
may be an over simplification that must be addressed prior to extrapolating mutant channel effects 
on the action potential. A straightforward approach to addressing this question is to perform single-
channel recording on both mutant channels at room and physiologic temperature and comparing 





Tissue-specificity of LQT3 Pathophysiology and Pharmacology 
The heart is not only comprised of epicardial ventricular tissue, but also of endo- and mid-
myocardial cells, atrial myocytes, and specialized conduction tissues such as the sinoatrial node, 
atrioventricular node, and His-Purkinje system. Each of these cell types express a different profile 
of channels, transporters, pumps, and Ca2+ handling machinery that result in tissue-specific action 
potential waveforms. While it is the ventricular action potential prolongation that gives rise to QT 
prolongation, recent work has demonstrated that Purkinje cells from the mouse heart are 
Figure 4.2. Tissue-specificity of INaL in LQT3. A) Epicardial action potential waveform from the O’Hara-
Rudy ventricular myocyte model during steady-state pacing at 1Hz. B) Purkinje cell action potential 
waveform from the Iyer-Sampson-Kass model during steady-state pacing at 1Hz. C) Peak INa in WT, 
F1473C and DKPQ in action potential-clamp simulations using the epicardial waveform. D) Peak INa in 
WT, F1473C and DKPQ in action potential-clamp simulations using the Purkinje waveform. E) Stimulation 
by the epicardial waveform results in INaL of similar magnitude from F1473C and DKPQ. F) Stimulation 
by the Purkinje waveform results in INaL of that is substantially larger in F1473C than in DKPQ. 
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particularly susceptible to prolongation and EAD formation by INaL and may be a primary source 
of arrhythmogenesis46.  
Additional simulations using models of bursting and late reopening channels suggested 
that the tissue-specific effects of INaL are also mutation-dependent42. Experiments and models 
presented in Chapters 1 and 2 demonstrate that F1473C and ∆KPQ mutations result in different 
effects on channel gating that alter the time- and voltage-dependent distribution of channel states. 
Compared to the ventricular action potential (Figure 4.2a), the Purkinje action potential (Figure 
4.2b) has a higher resting membrane potential, lower plateau potential, slower repolarization 
phase, and longer APD90. The voltage-dependent properties of mutant channels are therefore 
likely to respond in a tissue-specific manner. We used these action potential waveforms in voltage-
clamp simulations of F1473C and ∆KPQ currents at room temperature. Both voltage waveforms 
elicited larger peak currents in F1473C channels than from WT or ∆KPQ because the depolarizing 
shift in steady state inactivation results in a larger fraction of available channels at the resting 
membrane potential (Figures 4.2c and d). In simulations using the epicardial action potential, INaL 
from the two mutant channels was similar (Figure 4.2e). When a Purkinje action potential 
waveform is applied, INaL from F1473C is dramatically larger than INaL from ∆KPQ (Figure 4.2f), 
consistent with previous models of late reopening channels42. The lower plateau potential results 
in slower voltage-dependent inactivation accentuating the effects of the late reopening pathology, 
and the slow repolarization phase allows channels to recover prematurely in F1473C but not 
∆KPQ.  
If our mutations exhibit differential responses to ventricular and Purkinje action potentials 
because the voltage waveforms alter the distribution of channel states, then it stands to reason that 
the pharmacology of state-dependent channel inhibitors will also exhibit tissue-specific inhibition 
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of peak and late INa. Moreover, the expression of other ion channels with off-target effects may 
vary between tissue types, such as the additional INaL provided by expression of Nav1.1 in the 
Purkinje118, 119. Integration of mutant and drug models into whole ventricular and Purkinje models 
will allow for the prediction of antiarrhythmic – or for that matter, proarrhythmic – effects of INa 
inhibitors that may not manifest as clinically measurable changes in QT-interval. Multi-scale and 
multi-tissue in silico screening can therefore serve an important role in drug discovery and safety 
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